All posts by CHOC Childrens

Dr. Kushal Bhakta

Bhakta, Kushal – MD

Dr. Kushal Y. Bhakta has joined the Neonatology Division of the CHOC Specialists.

Dr. Bhakta is board certified in pediatrics and neonatal-perinatal medicine.
He received his medical degree from Baylor College of Medicine and completed his pediatric residency and neonatal-perinatal fellowship training at Baylor College of Medicine Affiliated Hospitals, Houston, Texas.

Dr. Bhakta is a graduate of the Educational Scholars. He is available to see patients at CHOC Children’s of Orange County and Pomona Valley Medical Center.

Arpan Global Charities – Mission Hangzhou, ChinaApril 8-18, 2011

Arpan Global Charities (AGC)

AGC, a medical volunteer organization, was founded in 2005 by Dr. Kukreja, a neonatologist at CHOC in California.

The mission of AGC is to protect the health, give hope and education the medically underserved populations around the world, and to provide humanitarian assistance in areas of need.

For more information on Arpan Global Charities, please open the full brochure below or visit their website at:

AGC_brochure2

Dr. Nandini Arul

Arul, Nandini – MD

Nandini Arul, M.D. is a CHOC Specialists Neonatologist, board certified in Pediatrics and Neonatal Perinatal Medicine. She served her Neonatal Fellowship at the Children’s Hospital of Wisconsin and completed her pediatric residency from the University of Illinois at Chicago. Dr. Arul received her medical degree from Madras University in India.

 

Dr. Arul has served as an assistant professor of Pediatrics with the Medical College of Wisconsin. Her areas of interest include Pulmonary hypertension of the newborn and enhancing learning with neonatal resuscitation simulation.

 

Dr. Hanh-Uyen Nguyen-Tang

Nguyen-Tang, Hanh-Uyen – MD (UCI)

Hanh-Uyen Nguyen-Tang, M.D. is a CHOC Specialists Critical Care physician board certified in General Pediatrics. Dr. Nguyen-Tang attended medical school at the University of Geneva, Faculty of Medicine, Switzerland. She started her pediatric residency training in Pourtales Hospital, Neuchatel, Switzerland and continued on to pediatric surgery residency training at the University Hospital of Geneva, Switzerland. She completed her residency training program at UC Irvine Medical Center, Irvine, California.

 

Dr. Nguyen-Tang is a member of the American Academy of Pediatrics and the Orange County Medical Association. Dr. Nguyen-Tang speaks fluent English, French, German and Vietnamese.

 

Dr. Amanda Fernandez

Fernandez, Amanda – MD

Amanda Fernandez, M.D. is a CHOC Specialists Neurologist, board certified in Pediatrics and Child Neurology. Dr. Fernandez received her medical degree from the University of the East in Quezon City, Philippines.

 

After moving to the United States, Dr. Fernandez completed her pediatric residency at State University of New York in Brooklyn, NY. Dr. Fernandez completed a fellowship in pediatric neurology at the University of Miami/Jackson Memorial Medical Center.

 

Dr. Fernandez has served Associate Clinical Professor, Department of Pediatrics, University of California, San Francisco and Medical Director of the Muscular Dystrophy Association Clinic.

 

Dr. Fernandez’s research has included a Prospective study of Neurologic Development in Infants at Risk for Human Immunodeficiency virus (HIV-1) Infection and Compassionate Use of Felbamate in Pediatric Subjects with Epilepsy. Dr. Fernandez is a member of the American Academy of Neurology, American Epilepsy Society and the Child Neurology Society.

 

Dr. Anup Patel

Patel, Anup – MD

Dr. Anup Patel is board certified in pediatrics and board eligible in pediatric gastroenterology. He received his medical degree from Albany Medical College, Albany NY. Dr. Patel completed his pediatric residency training at University of Nevada School of Medicine, Las Vegas, NV, followed by fellowship training in pediatric gastroenterology at Stanford University, Palo Alto, CA. Dr. Patel holds awards from Stanford University for Transplant and Tissue Engineering Endowment and Alan M. Krensky Endowed Clinical Fellow. Dr. Patel is available to see patients at CHOC Children’s of Orange County, CHOC Children’s at Mission and other select Orange County locations.

Dr. Jeffrey Ho

Ho, Jeffrey – DO

Dr. Jeffrey Ho serves as medical director of endoscopy services at CHOC. He works closely with the Medical Director of Anesthesia and the Medical Director of O.R. as well as the pulmonary and Gastroenterology physicians to enhance endoscopy services in the surgical services areas.

Dr. Ho is board certified in pediatrics and pediatric gastroenterology. He received his Doctor of Osteopathy degree from Touro University College of Osteopathic Medicine in Vallejo, California. Dr. Ho completed his pediatric residency training at the University of Nevada School of Medicine in Las Vegas, Nevada, followed by a fellowship in pediatric gastroenterology at the University of California Los Angeles, Los Angeles, CA Dr. Ho is fluent in Mandarin Chinese. He is available to see patients at CHOC Children’s of Orange County, CHOC Children’s at Mission and other select Orange County locations.

Dr. Jennifer Crisp

Ho, Jennifer Crisp – MD

Dr. Jennifer Crisp Ho is Hospitalist physician with the CHOC Specialists. Dr. Ho is board certified in pediatrics with the American Academy of Pediatrics. She completed her medical degree at the University of California Irvine, Irvine, CA and completed her residency at Children’s Hospital of Orange County. Dr. Ho speaks medical Spanish and is available to see patients at CHOC Children’s of Orange County and other select Orange County locations.

Dr. Jason Cook

Cook, Jason E. – MD

Jason Cook, M.D. is a CHOC Specialists Critical Care physician and board certified in Pediatrics and Pediatric Critical Care. Dr. Cook completed medical school at the University of Vermont College of Medicine, Burlington, Vermont. His residency training was completed at King/Drew Medical Center, Los Angeles, California where he also served a year as Chief Resident. Following completion of his residency, Dr. Cook served his fellowship in Pediatric Critical Care at Massachusetts General Hospital, Boston, Massachusetts.

 

Dr. Cook’s areas of research interest include teaching leadership in Pediatric CCU using High Fidelity Simulation and Incidence and description of morbidities during Hyperbaric Oxygen Therapy.

 

Education

CHOC Residency Program

 

Welcome to the CHOC Pediatric Residency Program website. We hope the information here will provide you with a good introduction to our program. Feel free to give us a call if you have any questions.
For more details, please click here.

 

Hematology / Oncology Fellowship Program

 

Welcome to the Children’s Hospital of Orange County’s (CHOC) Pediatric Hematology/Oncology Fellowship Program website. The information in this site will serve as an introduction to our program. The fellowship program is a three year program encompassing a clinical year followed by two years of clinical and basic research.
For more details, please click here.

CHOC Specialists Administration

CHOC Specialists – Administration Team

Jason Culp, VP CHOC Children’s Specialist
Email: Jason.Culp@choc.org
Phone: (714) 509-4134

Kalman Portman, VP CHOC Network – Finance
Email: Kalman.Portman@choc.org
Phone: (714) 509-3763

Business Office

Mike Cademartori
Director, Physician Business Services
Email: mcademartori@choc.org
Phone: (714) 509-7861

Mark Kelly, Director, Revenue Cycle Support
Email: mkelly@choc.org
Phone: (714) 509-7861

Managed Care

Mariam Elqura, Manager, Managed Care Contracts
Email: melqura@choc.org
Phone: (714) 509-4152

Links to Organizations and Online Communities

Autism Speaks was founded in February 2005 by Bob and Suzanne Wright, grandparents of a child with autism. Their longtime friend Bernie Marcus donated $25 million to help financially launch the organization. Since then, Autism Speaks has grown into the nation’s largest autism science and advocacy organization, dedicated to funding research into the causes, prevention, treatments and a cure for autism; increasing awareness of autism spectrum disorders; and advocating for the needs of individuals with autism and their families.
California Chapter 4, American Academy of Pediatrics is dedicated to achieving optimal health for all Orange County children by promoting pediatric excellence. The Chapter provides evidence-based recommendations for child health to pediatricians, parents, professionals and public policy makers.
Neurologic education is one of the AAN’s core values. The AAN extends this beyond its membership to K-12 students, college students, medical students, residents, fellows, neurologists in practice and Academia, and non-neurologist physicians.
Autism Awareness Centre hosts conferences across Canada and the UK, while ensuring books, articles and resource supports are readily available to all communities keeping parents and professionals on the cutting edge of new information. Autism Awareness Centre is leading the way because we “believe in change”.
The Autism Society, the nation’s leading grassroots autism organization, exists to improve the lives of all affected by autism. We do this by increasing public awareness about the day-to-day issues faced by people on the spectrum, advocating for appropriate services for individuals across the lifespan, and providing the latest information regarding treatment, education, research and advocacy.
The Federation is a center for parents and parent organizations to work together on behalf of children with special needs and their families. Organized in 1975 as a coalition of parent groups representing children with a variety of disabilities, the Federation offers workshops and training, advocacy and resources to parents of children with special needs and the professionals who serve them.
Epilepsy Alliance of Orange County is a community-based organization specifically addressing the needs of children and adults with epilepsy and their families in Orange County. It was created to empower those fighting against this life-altering condition to achieve the ultimate goal of becoming seizure-free.
Autism Spectrum of Support was founded in October 2003 in Irvine, CA as the Orange County Asperger Support Group, by two fathers looking to provide support for local parents, children and adults with Aspergers, High Functioning Autism and PDD-NOS. Through their leadership and innovation, it quickly grew to encompass much of Orange County, and currently holds support group meetings in Newport Beach and Placentia. Monthly activity groups are now held throughout Orange County.
The Asthma and Allergy Foundation of America (AAFA), a not-for-profit organization founded in 1953, is the leading patient organization for people with asthma and allergies, and the oldest asthma and allergy patient group in the world.
The American Asthma Foundation (AAF) is the only national advocacy group devoted solely to asthma, a chronic condition affecting 23 million Americans. AAF’s mission is to improve treatment, prevent, and find a cure for the disease.
Since 1980, the Make-A-Wish Foundation® has enriched the lives of children with life-threatening medical conditions through its wish-granting work. The Foundation’s mission reflects the life-changing impact that a Make-A-Wish® experience has on children, families, referral sources, donors, sponsors and entire communities.
CureSearch unites the world’s largest childhood cancer research organization, the Children’s Oncology Group, and the National Childhood Cancer Foundation through our mission to cure childhood cancer. Research is the key to the cure.
The American Society of Pediatric Hematology/Oncology (ASPHO) is a multidisciplinary organization dedicated to promoting optimal care of children and adolescents with blood disorders and cancer by advancing research, education, treatment and professional practice.
The Childhood Leukemia Foundation is a national non-profit organization that offers a wide range of services at no charge to children living with cancer and their families. Our goal is to make sure children battling cancer know they are not alone
The mission of the Cystic Fibrosis Foundation, a nonprofit donor-supported organization, is to assure the development of the means to cure and control cystic fibrosis and to improve the quality of life for those with the disease.
The American Academy of Pediatrics (AAP) and its member pediatricians dedicate their efforts and resources to the health, safety and well-being of infants, children, adolescents and young adults.
The mission of Ronald McDonald House Charities (RMHC) is to create, find and support programs that directly improve the health and well being of children.
The American Society of Hematology (ASH) is the world’s largest professional society concerned with the causes and treatments of blood disorders. The mission of the Society is to further the understanding, diagnosis, treatment, and prevention of disorders affecting the blood, bone marrow, and the immunologic, hemostatic and vascular systems, by promoting research, clinical care, education, training,

The mission of the American Academy of Ophthalmology is to advance the lifelong learning and professional interests of ophthalmologists (Eye M.D.s) to ensure that the public can obtain the best possible eye care.
Our mission is to prevent and cure diabetes and to improve the lives of all people affected by diabetes.
We lead the fight against the deadly consequences of diabetes and fight for those affected—by diabetes.

  • We fund research to prevent, cure and manage diabetes.
  • We deliver services to hundreds of communities.
  • We provide objective and credible information.
  • We give voice to those denied their rights because of diabetes.

‘Too Young for Cancer’ and Demanding Action

The grim statistics have become a rallying point for activist groups: Some 72,000 Americans aged 15 to 39 are diagnosed with cancer every year, and more than 10,000 die. They make up less than 10% of all cancer patients, but survival rates for teens and young adults have barely budged since 1975, while those for children and older people have made dramatic gains.

To read more on this article click here.

Rheumatology – Contact Info and Locations

To Schedule A Consultation or Office Visit

In addition to inpatient consultation, CHOC Specialists rheumatology physicians provide outpatient services at both CHOC and CHOC at Mission.

Appointments: 888-770-2462

Fax: 855-246-2329

After Hours: 714-765-6620

Main Office: 714-509-8617

Locations

CHOC Clinic – Specialty Care

CHOC Health Center, Mission Viejo

CHOC Health Center, Corona

CHOC Specialty Center, Newport Beach

Pulmonology – Contact Info and Locations

To Schedule A Consultation

CHOC Specialists Pulmonology physicians are available 24-hours-a-day for consultation.

Appointments: 888-770-2462

Fax: 855-246-2329

After Hours: 866-316-3345

Locations

CHOC Clinic – Specialty Care

CHOC Health Center at PIH Health

CHOC Health Center, Mission Viejo

CHOC Health Center, Corona

CHOC Health Center, Huntington Beach

CHOC Sleep Center

CHOC at Mission Hospital Sleep Center

Neurology – Contact Info and Locations

To Schedule an Appointment or a Consultation

In addition to on-site consultation, CHOC Specialists neurology physicians provide outpatient services at both CHOC and CHOC at Mission.

Appointments: 888-770-2462

Fax: 855-246-2329

After Hours: 866-316-3347

Locations

CHOC Neuroscience Institute Outpatient Center

CHOC Health Center at PIH Health

CHOC Health Center, Mission Viejo

CHOC Health Center, Corona

CHOC Specialty Center, Newport Beach

Thompson Autism and Neurodevelopmental Center at CHOC

Nephrology – Contact Info and Locations

To Schedule a Consultation or Office Visit

CHOC Specialists nephrology physicians are available for inpatient consultation 24 hours a day. Outpatient appointments may also be scheduled during convenient office hours.

Appointments: 888-770-2462

Fax: 855-246-2329

After Hours: 714-765-6617

Locations

CHOC Specialty Center, Newport Beach

CHOC Health Center, Corona

CHOC Health Center, Huntington Beach

CHOC Health Center at PIH Health

CHOC Health Center, Mission Viejo

CHOC Clinic – Specialty Care

Neonatology – Contact Info and Locations

To Schedule A Consultation

In addition to on-site consultation, CHOC Specialists neonatology physicians provide outpatient follow-up at CHOC.

Appointments: 888-770-2462

Administration Office: 714-509-4373

Fax: 714-509-7800

HRIF Appointments and Consultations: 714-509-7896

Locations

CHOC Clinic – Specialty Care

CHOC Hospital

CHOC at Mission Hospital

Hoag Memorial Hospital Presbyterian

Parkview Community Hospital Medical Center

Pomona Valley Hospital Medical Center

St. Joseph Hospital

St. Jude Medical Center

St. Mary Medical Center – Apple Valley

Western Medical Center – Santa Ana

Hospitalist – Contact Info and Locations

24-Hour Notification of Emergency or After-Hours Admissions

CHOC Specialists hospitalist physicians are available to access patients throughout the day to identify the optimal time for discharge. Referring primary care physicians receive a complete discharge order sheet within 24- hours, including all pertinent test results and surgical information.

To Schedule an Admission

Patients may be admitted at CHOC to the CHOC Specialists Hospitalist service 24 hours a day, 7 days a week.

CHOC Hospital in Orange:

714-509-8400 – To admit a patient, ask for Admitting Department and let them know you want to admit your patient to a CHOC Specialists hospitalist

714-997-3000 – Ask for CHOC Specialists hospitalist on call to talk with the hospitalist directly

714-509-8826 – Administration Office

CHOC at Mission Hospital:

949-365-2401 – To admit a patient at CHOC Mission, ask for the hospitalist on call

CHOC at Pomona Valley Hospital Medical Center (pediatric floor):

909-865-9871 – To admit a patient at CHOC Pomona, ask for the hospitalist on call

Locations

CHOC Hospital

CHOC at Mission Hospital

Pomona Valley Hospital Medical Center

Gastroenterology – Contact Info and Locations

To Schedule a Consultation or Office Visit

CHOC Specialists Gastroenterology physicians are available for inpatient consultation 24 hours a day, 7 days a week. Outpatient appointments may be scheduled at several convenient office locations offering flexible hours.

Main Office: 714-509-4099

Appointments: 888-770-2462

Fax: 855-246-2329

After Hours: 866-283-3181

Locations

CHOC Specialty Center, Newport Beach

CHOC Health Center, Corona

CHOC Health Center at PIH Health

CHOC Health Center, Mission Viejo

CHOC Clinic – Specialty Care

Cardiology – Contact Info and Locations

To Schedule a Consultation or Office Visit

With 24-hour availability, CHOC Specialists Cardiology physicians provide on-site consultation at CHOC, CHOC at Mission and select Orange County hospitals. Outpatient offices are conveniently located throughout the greater Orange County area.

Phone: 714-509-3939

Fax: 714-509-3949

After Hours: 866-316-3382

Locations

CHOC Outpatient Heart Center

CHOC Specialists Cardiology

CHOC Health Center at PIH Health

CHOC Health Center, Mission Viejo

CHOC Health Center, Corona

CHOC Specialty Center, Newport Beach

CHOC Clinic – Specialty Care

Prevention of Sudden Death in Athletes

From The Orange County Register

 

By LANDON HALL – THE ORANGE COUNTY REGISTER

 

COSTA MESA – For the second straight year, doctors, educators, administrators and parents gathered Saturday to talk about something they already know: that portable defibrillators can save the life of a young athlete stricken by sudden cardiac arrest.

 

And yet their goal of getting a defibrillator in every school seems far off, slowed by the recession and legal issues.

 

Dr. Anthony Chang, medical director of the pediatric heart center at Children’s Hospital of Orange County, told dozens of people at the “Life-Threatening Events Associated With Pediatric Patients in Sports” symposium that great progress has been made since the inaugural event a year ago.

 

“We’re literally at the cusp of breaking through in terms of permanent action,” he said.

 

The conference, founded by Chang and Dr. Dan Cooper of UCI, has established the goal of making Orange County a model in protecting young people who play organized sports. Its goals include: comprehensive screening, including an electrocardiogram for athletes prior to competition; CPR training for faculty and students; and increasing the number of automatic external defibrillators, devices used to shock the heart into beating again.

 

Reaching this level of preparedness is expensive. Take the defibrillator goal alone: One unit can cost $1,500 to $3,000, and require training and maintenance. Of the 29 school districts in the county, 10 have at least one.

 

“One on every campus is ideal,” said Pamela Kahn, a registered nurse who’s the coordinator for health and wellness for the county Department of Education. “In the economic climate, that’s certainly difficult. But it’s possible.”

 

With every district struggling with diminished funds from the state, advocates are trying to find private-sector alternatives, with help from families who have dealt first-hand with sudden cardiac arrest.

 

Kirk and Lori Stuewe of Anaheim Hills told the crowd inside Department of Education headquarters about their 14-year-old daughter, Shauna. She was a seemingly healthy 14-year-old freshman at Esperanza High School and a “flier” on the junior varsity cheerleading squad. She had just completed a routine stunt when she complained of dizziness and fainted. She later died.

 

It wasn’t until three years later that doctors were able to determine the cause of death: CPVT, a genetic mutation blamed in about 15 percent of deaths from sudden cardiac arrest in young people.

 

Her parents created the Shauna Ann Stuewe Foundation and have used donations and fund-raisers to place 37 defibrillators in area schools. They also go into schools to inspect existing machines, and they’ve often found troubling signs: The machine often has pads or batteries that need replacing, or it’s locked up in a principal’s office, where it’s not easily accessible.

 

“Some look like they take it on the football field with them, which is fine,” Lori Stuewe said. “But you have to clean and maintain them. You can’t have dirt all over them.”

 

Money isn’t the only obstacle to getting more machines in schools. State law requires that any school with a machine must ensure that someone trained in its operation be available during school functions, even if only a few students are present. Other kinds of institutions don’t have that restriction.

 

“I could put (one) in central jail in Santa Ana much easier than I can put one in my daughter’s middle school,” said Dr. Sam Stratton, medical director of the county’s Emergency Medical Services.

 

The Department of Education’s lobbyist will push for that provision of the law to be changed. Others are confident that more defibrillators will get into schools.

 

“With the budget crisis the way it is, there is an absolute 100 percent commitment that, budget be damned, we’re going to figure this out,” said Bruce Baron, principal at South Lake Middle School in Irvine.

Rheumatology

CHOC Specialists Rheumatology physicians are committed to the early intervention necessary to maximize quality of life for children with rheumatic diseases. These highly experienced and talented physicians provide innovative, yet cost-effective inpatient and outpatient care for inflammatory and non-inflammatory rheumatic diseases, including:

  • Autoinflammatory/periodic fever syndromes
  • Chronic iritis
  • Dermatomyositis
  • Dysautonomia syndromes
  • Hypermobility-associated musculoskeletal pain
  • Iridocyclitis
  • Juvenile ankylosing spondylitis (JAS)
  • Juvenile idiopathic arthritis (JIA)
  • Pain amplification syndrome and related pain syndromes
  • Scleroderma
  • Systemic lupus erythematosus (SLE)
  • Vasculitis (including ANCA-associated)

Clinical services are complemented by the multidisciplinary care provided by other pediatric subspecialists, nurses, pharmacists, therapists, clinical dietitians and social workers at CHOC and CHOC at Mission.

Regionally Recognized for Clinical Excellence

Early intervention is crucial to long-term prognosis and quality of life for a child with rheumatic disease. As part of their professional commitment to serving this especially vulnerable patient population, CHOC Specialists Rheumatology physicians often travel outside Orange County to assess a child in need, in addition to providing outreach to local hospitals.

As CCS-accredited providers in rheumatic disease, CHOC Specialists Rheumatology physicians are available for on-site evaluation within a three-county radius: Orange, Riverside and San Bernardino counties. They are also affiliated with the American Juvenile Arthritis Organization and serve on the board of the Arthritis Foundation.

Care Available for the “Whole Child” and Family

As part of the multidisciplinary treatment milieu, clinical services offered include medical evaluation and therapy, psychosocial support, nursing education, and occupational and physical therapy. Families are encouraged to participate in rheumatic disease support groups.

A CHOC Specialists Rheumatology physician also provides medical care at Camp Esperanza, a summer camp sponsored every year by the Arthritis Foundation for children with rheumatic diseases.

Actively Participating in the Latest Bench and Clinical Research

CHOC Specialists Rheumatology physicians serve as principal investigators for several research studies into inflammation, a significant factor in such autoimmune diseases as juvenile rheumatoid arthritis, systemic lupus, multiple sclerosis and scleroderma. Activities are focused on the genetics of autoimmune disease and DNA repair. Their involvement in this leading-edge research gives patients access to newer medications and treatment.

Pulmonology

Available for consultation 24-hours-a-day, CHOC Specialists Pulmonology physicians provide comprehensive clinical services for a full range of genetic, developmental, structural and acquired disorders of the lungs and respiratory system. Board certified in pediatric pulmonology, these highly experienced physicians provide innovative, yet cost-effective inpatient and outpatient care for common and unusual disorders:

  • Recurrent pneumonia
  • Cystic fibrosis
  • Severe asthma
  • Chronic cough
  • Airway problems
  • Sleep apnea
  • Chronic lung disease
  • Congenital lung abnormalities
  • Bronchopulmonary dysplasia
  • Tracheotomy care
  • Immunology disorders
  • Home ventilators
  • Neuromuscular problems
  • Chronic care of technology dependent children

Regionally Recognized for Excellence : Available for consultation throughout the greater Orange County area, CHOC Specialists Pulmonology physicians are CCS-accredited providers for cystic fibrosis and chronic lung disease. They direct the Cystic Fibrosis Care, Research and Treatment Center at CHOC, which is also accredited by the Cystic Fibrosis Foundation.

In addition to providing medical direction for inpatient and outpatient pulmonology services at both CHOC and CHOC at Mission, CHOC Specialists Pulmonology physicians serve as Directors of the CHOC Respiratory Institute and the CHOC Asthma and Chronic Lung Program, as well as providing inpatient consultation at several community hospitals. They also direct pediatric sub-acute units at hospitals in Orange and Whittier.

Specialized Pediatric Procedures and Services : Fully equipped with sophisticated, leading-edge technology, CHOC Specialists Pulmonology physicians provide tertiary-level, pediatric subspecialty services, including:

  • Pediatric pulmonary function testing at CHOC, including spirometry, lung volumes, diffusion capacity, exercise stress testing and the ability to study young children and those with disabilities
  • Fiber optic bronchoscopy, including a wide range of bronchoscopes for different sizes and problems
  • Full respiratory care program with multiple options for bronchial clearance
  • Ongoing management of children with bronchopulmonary dysplasia (BPD) and other oxygen-dependent patients
  • Apnea diagnostic center and monitor program, including education for parents of children with sleep apnea
  • Cystic Fibrosis Care, Research and Treatment Center
  • Respiratory Syncytial Virus Prevention Clinic, offering risk assessment and prophylaxis of high risk infants
  • Neuromuscular evaluation and treatment for respiratory complications of neuromuscular disease

Inpatient services provided by CHOC Specialists Pulmonology physicians are complemented by the multidisciplinary care provided by pediatric subspecialty physicians, nurses, pharmacists, therapists, clinical dietitians and social workers at CHOC, the only pediatric hospital serving Orange County.

Family Support and At-Home Care

CHOC Specialists Pulmonology physicians offer a home ventilator program and consultation for chronic, oxygen-dependent patients. Home intravenous therapy is available for children with cystic fibrosis and other lung diseases.

Access To the Latest Clinical Research

CHOC Specialists Pulmonology physicians participate in clinical research, giving patients access to newer medications and treatment. They serve as principal investigators for multiple ongoing studies for new medications developed for cystic fibrosis, bronchopulmonay dysplasia, asthma and other pediatric lung diseases.

Ophthalmology

CHOC Children’s Specialists Ophthalmology provides the latest, most comprehensive treatment for pediatric eye disorders. We offer both basic eye care and specialty care, as well as surgery, to protect and restore vision for babies, children and teens.

Children often cannot tell you when they are having problems with their vision. We use innovative techniques to test a child’s vision that are different than methods used at adult practices, all in a pediatric setting.

What We Treat

We treat the full spectrum of pediatric eye conditions, including but not limited to:

  • Amblyopia (lazy eyes)
  • Childhood glaucoma (infantile, juvenile and traumatic)
  • Double vision (diplopia)
  • Droopy eyelids (ptosis)
  • Eye inflammation (uveitis)
  • Infantile and childhood cataracts
  • Nasolacrimal duct obstruction (blocked tear ducts)
  • Refractive errors (need for glasses/contacts)
  • Retinopathy of prematurity and its complications
  • Strabismus (crossing or drifting of the eyes)
  • Tearing eyes
  • Traumatic eye injuries.

Our pediatric ophthalmologists also treat eye problems related to other diseases such as diabetes, sickle cell disease, juvenile rheumatoid arthritis, metabolic disorders, brain tumors, genetic and chromosomal disorders, and craniosynostosis.

Vision Screenings

Early diagnosis and treatment is important to ensure a child’s vision develops correctly and to prevent long-term problems. We offer comprehensive eye screenings for every age.

Experts in Pediatric Eye Surgery

Because we perform eye surgery on the smallest patients, including babies as young as one day old, we use the least invasive techniques possible and unique methods to help ensure a child has a lifetime of vision. Eye surgery is performed at the CHOC Children’s surgery center, featuring pediatric-trained anesthesiologists, operating rooms and equipment that are customized for kids, and child life specialists who are at the bedside to reduce a child’s stress. Learn more about having surgery at CHOC.

Innovations in Pediatric Glaucoma Management

CHOC Children’s Specialists Ophthalmology is one of only a handful of centers in the United States that performs illuminated microcatheter-facilitated trabeculotomy, which is a minimally invasive surgical procedure for pediatric glaucoma management. This highly specialized treatment is the newest approach to lowering intraocular pressure in the eye with minimal risk for complications.

Dr. Lilibeth Torna

Torno, Lilibeth L. – MD

Lilibeth L. Torno, M.D., is board certified in pediatrics and pediatric hematology/oncology. Dr. Lilibeth Torno leads the Ambulatory Care Services of The CHOC Cancer Institute and directs the CHOC Long Term Follow-up Clinic for survivors of childhood cancer and is an Associate Clinical Professor at UC Irvine.

 

The outpatient clinic provides comprehensive care of children undergoing chemotherapy, as well as those who have completed therapy. Dr. Torno completed her fellowship training at Children’s Hospital of Los Angeles. She completed her residency at CHOC in Orange, California. She attended medical school at University of Santo Tomas, Manila, Phillipines.

 

Dr. Torno was voted as one of Orange County’s Top Doctors in 2009.

Dr. Elyssa Rubin

Rubin, Elyssa – MD

Elyssa Rubin, M.D., is board certified in pediatrics and pediatric hematology/oncology, and is a Clinical Instructor at UC Irvine.

 

Dr. Rubin completed her medical school training at the Sackler School of Medicine, NY State/American Branch in Tel Aviv, Israel. She completed her pediatric internship and residency training at Kaiser Permanente Los Angeles Medical Center and her fellowship in pediatric hematology/oncology at Children’s Hospital of Orange County.

 

As a research fellow, Dr. Rubin’s focus was on new therapeutic targets for osteosarcoma. She has special interests in sarcomas and the histiocytic disorders.

 

Dr. Ivan Kirov

Kirov, Ivan I. – MD

Ivan Kirov, M.D., is a board certified pediatric hematologist/oncologist. He is CHOC Children’s director of palliative care and director of the lymphoma and recurrent cancer programs in CHOC’s Cancer Institute. Dr. Kirov earned his medical degree from the Medical Academy in Sofia, Bulgary in 1979. He did his residency and fellowship in Bulgaria where he went on to become an accomplished pediatric hematologist/oncologist for more than 20 years.

 

In 1992, Dr. Kirov moved to the United States and became a visiting fellow in the bone marrow transplant program at the Johns Hopkins Hospital Oncology Center. He then went on to complete a residency in pediatrics at Westchester County Medical Center and postdoctoral fellowship in pediatric hematology/oncology at CHOC. Dr. Kirov has been published in a number of journals including Bone Marrow Transplant and the Journal of Pediatric Hematology/Oncology

 

Dr. Kirov’s clinical interests include Hodgkin’s and non-Hodgkin’s lymphomas, recurrent cancers, and bone marrow transplants. He is engaged in a number of clinical research projects and is a co-investigator in all ongoing stage one oncology studies at CHOC. He is currently investigating effectiveness of the experimental drug Beudawustim in recurrent leukemia patients. He is also studying defibrotide in the treatment of veno-occlusive disease of the liver after bone marrow transplants.

 

Dr. Kirov is currently the recipient of two grants from the UCI Chao Family Comprehensive Cancer Center seed funding. One of his funded projects looks at whether loss of SXR expression or function is associated with B-cell lymphomas. The other study is a pilot project to investigate FGFR3 expression and mutations in pediatric patients.

 

Dr. Kirov was voted as one of Orange County’s Top Doctors in 2009 & 2010.

 

Published Works

 

Abla O, Sandlund JT, Sung L, Brock P, Corbett R, Kirov I, Griffin TC, Blaser S, Weitzman S. A case series of pediatric primary central nervous system lymphoma: favorable outcome without cranial irradiation. Pediatr Blood Cancer. 2006 Dec;47(7):880-5.

 

Neudorf S, Nourani A, Kempert P, Shen V, Sender L, Kirov I. Chemotherapy and donor leukocyte infusion for relapsed juvenile myelomonocytic leukemia (JMML). Bone Marrow Transplant, 2004; 33: 1069

 

Kirov I., Shen V., Lones MA.., Primary Central Nervous System B-Cell Lymphoma in Childhood. J Pediatr Hematol Oncol, April 2003; 25 (4): 29.

 

Kirov I., Neudorf S., Shen V., Lones MA., Peripheral T-Cell Lymphoma (Non-Anaplastic) in Childhood. J Pediatr Hematol Oncol, April 2003; 25 (4): 29.

 

Lones MA. , Kirov I., Cell Surface Targets For Monoclonal Antibody Therapy in Lymphoid Neoplasms of Children and Adolescents. J Pediatr Hematol Oncol, April 2003; 25 (4): 80 – 82.

 

Lones MA., Kirov I., Said JM., Shinataku IP., Neudorf S. Post-transplant lympho-proliferative disorder after autologous stem cell transplantation in a pediatric patient. Bone Marrow Transplant 2000; Nov; 26 (9): 1021-1024.

 

Kirov I., and Neudorf S., Biology and clinical utility of hematopoietic stem cells. Pediatric Pathology and Molecular Medicine 2000; 19: 283-302.

 

Abu-Ghosh, Bracho F., Kirov I., and Cario MS., Hematopoietic Colony-Stimulating Factors In: Textbook of Critical Care, 4th Edition, Grenik, A (Ed), Philadelphia, Saunders, 2000; pp 542-561.

 

Konstantinov D., Bobev D., Michailov G., ………Kirov I. A seven years experience in treatment of childhood leukemia in Bulgaria. Pediatric Hematology Oncol 1998 Mar-April; 15(2): 157-164.

 

Kirov I., Slone V., at all. Generation of Dendritic Cells From Fresh and Cryopreserved, G-CSF Mobilized Peripheral Blood Mononuclear Cells of Patients with Breast Cancer. Proc. Am. Assoc. Cancer Res., 1999; 40: 573.

 

Presentations
Goldman S. , Kirov I., et al. IL-11 + G-CSF After High Dose Ifosfamide, Carboplatin and Etoposide Mobilizes Large Numbers of CD34+ and CD34+/41+ Progenitor Cells into Peripheral Blood Sufficient for Rapid Hematopoietic Reconstitution Post Myeloablative Therapy in Heavily Pretreated Pediatric Solid tumor Patients: ISEH’98, August 1998, Vancouver, Canada.

 

Cairo M., Kirov I., et al. Recombinant Human Interleukin 11 Enhances Hematologic Recovery Following ICE Chemotherapy in Children with Solid Tumors and Lymphoma: Analysis of Hematopoietic Responses, Cytokine Induction, Pharmacokinetics and Stem Cell Mobilization: ASCO, 34th Annual Meeting, May 1998, Los Angeles, California.

 

Goldman S., Kirov I., et al. IL – 11 + G-CSF is an Excellent Cytokine Combination for Peripheral Blood Progenitor Cell Mobilization in Children Following ICE Chemotherapy: ASBMT, Annual Meeting, March 1997, Miami, Florida.

 

Kirov et al. Recombinant Human Interleukin 11 (Neumega®) is Tolerated at Double the Adult Dose and Enhances Hematopoietic Recovery Following ICE Chemotherapy in Children: Correlation with Rapid Clearance, Lack of Induction of Inflammatory Cytokines and Mobilization of Early Progenitor Cells: ASH, 39th Annual Meeting, December 1997, San Diego, California.

 

Esparza, Samuel D. – MD

Samuel D. Esparza, M.D. is a pediatric hematologist/oncologist and he is an Assistant Clinical Professor at UC Irvine.

 

Dr. Esparza attended medical school at the University of California, Los Angeles School of Medicine. He also completed his residency in pediatrics and his fellowship in pediatric hematology/oncology at Mattel Children’s Hospital/UCLA. In addition, as a Specialty Training and Advanced Research Fellow at UCLA, he worked in cellular and molecular pathology. Dr. Esparza is board certified in pediatrics and board eligible in pediatric oncology/hematology. Dr. Esparza is fluent in Spanish. His philosophy of care is to provide the best possible care with compassion and competence to all patients regardless of race, creed, color, or economic background.

 

Oncology

The Oncology unit at CHOC is staffed with nurses specially trained to treat the complex conditions that accompany pediatric cancers. In addition, the 28-bed Hematology/Oncology unit and the 12-bed Oncology Intensive Care Unit (OICU) is the only dedicated pediatric program in Orange County. As part of the CHOC Cancer Institute, our program offers the latest in medical and surgical oncology including chemotherapy, radiotherapy and blood and marrow transplantation. The program brings together a full range of pediatric services and multidisciplinary care for our pediatric cancer patients and their families.

Internationally recognized for clinical excellence, CHOC Specialists Oncology physicians provide state-of-the-art diagnostic services and a full spectrum of treatment modalities for pediatric malignancies, including surgical oncology, chemotherapy, radiotherapy, and blood and marrow transplantation. Their services are complemented by the multidisciplinary care provided by other pediatric subspecialists, nurses, pharmacists, rehabilitation therapists, clinical dietitians, child psychologists and social workers at CHOC. Actively involved in clinical as well as translational research, these highly experienced, board certified pediatric oncologists provide patients with access to the latest, often break-through, treatments.

CHOC Specialists Oncology physicians are fully equipped with highly advanced technology available, including:

  • Advanced CT, PET, MRI and MRI spectroscopy for the diagnosis and staging of tumors
  • Sophisticated radiotherapy capabilities, including a new linear accelerator and CT-based planning system and simulator.

Internationally Recognized for Research

CHOC Specialists Oncology physicians serve as medical directors for the CCS-accredited inpatient and outpatient oncology program at CHOC, including The CHOC Cancer Institute. CHOC is an active member of the prestigious Children’s Oncology Group (COG), a National Cancer Institute-supported program offering patients access to state-of-the-art treatment through research.

By participating in clinical studies through COG and with pharmaceutical, biologic and device companies, CHOC Specialists Oncology physicians are able to provide patients with access to the latest therapeutic advances for cancer and for the side effects caused by cancer treatment.

Comprehensive Blood & Marrow Transplant Services

CHOC Specialists Oncology physicians direct the pediatric blood and marrow transplant program at CHOC, the only program of its kind serving Orange County children. This comprehensive program includes a stem-cell laboratory and umbilical cord blood bank.

Approved by the National Marrow Donor Program, services include pre- and post-transplant care for immune deficiency disorders, hematologic disorders, malignancies and genetic disorders. Transplantation is available using histocompatible, haploidentical and matched unrelated bone marrow and cord blood.

Working in Collaboration With Referring Physicians : Referring physicians are encouraged to participate in the treatment planning process and receive thorough update reports on a timely basis.

Peng, Ying – MD

Dr. Peng provides care for the full range of neurological conditions, with special interest in pediatric neuromuscular disease and Electromyography/Nerve Conduction Studies (EMG/NCV) in children. She is certified by the American Board of Pediatric Neurology and the Clinical Neurophysiology Subspecialty Board. Dr. Peng completed medical school at the Shanghai Medical University in China/University of Kansas Co-education Program. She did her internship in pediatrics and her residency in neurology at UCI. Her fellowships are in clinical neurophysiology at UCI and in neuroscience/molecular biology research at Northwestern University.

Dr. Patricia Veiga

Veiga, Patricia A. – MD

Pediatric nephrologist Patricia Veiga, M.D. specializes in treatment and management of the full spectrum of related kidney conditions. She completed her fellowship, residency and internship training at Children’s Hospital of Buffalo in New York. She received her medical training at Saint Louis University in Missouri. Dr. Veiga is board certified in pediatrics and pediatric nephrology.

Nephrology

Available 24-hours-a-day, 7 days a week, CHOC Specialists Nephrology physicians provide the comprehensive inpatient and outpatient care necessary to maximize quality of life for children with kidney diseases. These highly trained and skilled pediatric subspecialists work collaboratively with primary care physicians and pediatric urologists, meeting the medical and surgical needs of children with acute and chronic renal disease.

CHOC Specialists Nephrology physicians also serve as medical directors for the CHOC Pediatric Nephrology Program, the only CCS-certified center serving Orange County, and the pediatric dialysis unit at the St. Joseph Hospital Renal Center in Orange. Their services are complemented by the multidisciplinary care provided by other pediatric subspecialists, nurses, pharmacists, therapists, clinical dietitians, child psychologists and social workers at CHOC.

Regionally Recognized for Clinical Excellence: Early intervention and consultation with a CHOC Specialists Nephrology physician allows for timely diagnosis, intervention and treatment. Inpatient and outpatient consultation is available for all renal problems, including:

  • Hypertension
  • Nephrotic syndrome
  • Hematuria
  • Acute and chronic renal failure
  • Proteinuria
  • Cystic kidneys
  • Recurrent urinary tract infections
  • Renal anatomical abnormalities
  • Kidney stones
  • Calcium and phosphorus metabolism
  • Nephritis
  • Polyuria and polydypsia
  • Renal tubular acidosis and tubular disorders
  • Pre-renal transplant evaluation
  • Diabetic nephropathy
  • Post-renal transplant follow-up care

Specialized Pediatric Procedures

Highly experienced, CHOC Specialists Nephrology physicians have the expertise to perform the following specialized procedures:

  • Percutaneous renal biopsies using ultrasound guidance, and
  • State-of-the art renal replacement therapy for acute renal failure, including peritoneal dialysis, hemodialysis, and continuous renal replacement therapy using a blood pump for the smallest and most critically ill infants and children

Pediatric Renal Dialysis and At-Home Peritoneal Dialysis

CHOC Specialists Nephrology physicians serve as Medical Directors of the Pediatric Dialysis Unit at St. Joseph Hospital Renal Center, the only pediatric facility of its kind serving greater Orange County. They also provide specialized family training and comprehensive support for at-home peritoneal dialysis.

Family Education and At-Home Care

CHOC Specialists Nephrology physicians combine compassion with education to help parents and patients, as appropriate, understand and manage the condition. By involving the family in treatment planning, many complicated conditions may be managed within the comfort of the patient’s own home – avoiding costly hospitalization. Physicians are available 24-hours-a-day, 7 days a week for phone contact with parents to avoid unecessary trips to the Emergency Room.

Active Participants in the Latest Clinical Research

CHOC Specialists Nephrology physicians serve as principal investigators for several clinical research studies, providing patients with access to the newest treatment options available. Recent studies have included clinical trials to assess the effectiveness of a new anti-hypertensive medication, an active form of Vitamin D for dialysis patients, and a new, long-acting erythropoetin drug for anemia in patients with renal failure

Worcester, Carrie C. – MD

Dr. Worcester serves as the Director of CHOC Case Management and the Medical Director of the CHOC Early Development Assessment Center. She specializes in all aspects of neonatal medicine with expertise in the management of critically ill and pre-term newborns. Dr. Worcester is board certified in pediatrics and neonatal-perinatal medicine. She served her fellowship and residency at University of California, Irvine Medical Center in Orange. Additionally, she completed her internship at Harbor General Hospital, UCLA School of Medicine. She received her training at the University of Oregon Medical School in Portland.

Dr. Lawrence Wickham

Wickham, Lawrence – MD

Lawrence K. Wickham, M.D. is the Medical Co-Director of Neonatal Services at Hoag Memorial Hospital Presbyterian, Newport Beach. Dr. Wickham served a neonatology fellowship at Madigan Army Medical Center in Fort Lewis, Washington. He completed both his internship and residency at Tripler Army Medical Center in Honolulu, Hawaii, where he served as Chief Resident. He attended medical school at the Emory University School of Medicine, Atlanta, Georgia. Dr. Wickham is board certified in both pediatrics and neonatal/perinatal medicine. His honors include the Jonas Salk Mentor in Medicine Award in 2000 and California Perinatal Association’s Clinician of the Year in 1989.

 

As a CHOC Specialists neonatologist, Dr. Wickham’s goal is to provide the highest level of care for patients at delivery and during their stay in the Hoag Neonatal Intensive Care Unit (NICU). His special interests include care of the late preterm infant and support of families dealing with the stress of having their infant hospitalized in a NICU.

Dr. Katrina Tesmer

Tesmer, Katrina J. – MD

Katrina Tesmer, M.D. provides the full range of neonatal medical services. Dr. Tesmer serves as the Medical Director of the Neonatal Intensive Care Unit at Western Medical Center in Santa Ana. Dr. Tesmer is board certified in pediatrics and neonatal-perinatal medicine. She served her fellowship and residency through the University of Southern California and White Memorial Medical Center in Los Angeles, respectively. She graduated from the Medical School of Gdansk, Poland and completed her internship at Mlava Hospital in Poland.

Dr. Daniel Saesim

Saesim, Daniel D. – MD

Daniel Saesim, M.D. is a CHOC Specialists Neonatologist and is board certified in pediatrics and neonatology. Dr. Saesim is the Associate Director of the NICU at Parkvidew Community Hospital. Dr. Saesim received his M.D. degree from Loma Linda Medical School. He completed an internship, residency and a fellowship at the Loma Linda Medical Center, Loma Linda, California. Dr. Saesim is an Assistant Clinical Professor at UC Irivne.

Photo not available

Rehan, Virender K. – MD

Dr. Rehan treats the full spectrum of neonatal conditions. He is board certified in pediatrics and neonatal-perinatal medicine. He completed his fellowship training at the Health Sciences Center in Winnipeg, Manitoba, Canada. Dr. Rehan completed his residency at Royal Liverpool Children’s Hospital at Alderhey, Liverpool, England. He attended medical school at the University College of Medical Sciences, Delhi, India.

Photo not available

Patel, Dilip – MD

Dilip Patel, M.D. specializes in treating the full spectrum of neonatal conditions. Dr. Patel is board certified in pediatrics and board admissible in neonatal-perinatal medicine. He served his fellowship through the University of California, San Diego. He completed both his residency and internship at the University of Medicine and Dentistry of New Jersey in Newark. Dr. Patel received his medical training at Maharaja Sayajirao University in India.

Dr. Anthony Liu

Liu, Anthony – MD

Anthony Liu, M.D. is board certified in pediatrics and neonatal-perinatal medicine. He received his medical degree from the University of Vermont College of Medicine, and his residency and fellowship training were completed at the Loma Linda University Medical Center. Dr. Liu has special interests in medical informatics and patients with retinopathy of prematurity. Dr. Liu is an Assistant Clinical Professor at UC Irivne.

Dr. Christine Kurlawalla-Martinez

Kurlawalla-Martinez, Christine – MD

Christine Kurlawalla-Martinez, M.D., is board certified in pediatrics and neonatal-perinatal medicine. Dr. Kurlawalla-Martinez is a CHOC Specialists Neonatologist who cares for patients in the NICU and she is a Clinical Instructor at UC Irvine.

 

Dr. Kurlawalla-Martinez attended medical school at the University of California, Irvine College of Medicine. She completed her pediatric residency at King-Drew Medical Center in Los Angeles and completed her fellowship training in neonataology at Mattel Children’s Hospital at UCLA. Dr. Kurlawalla-Martinez is available to see patients at Children’s Hospital of Orange County (CHOC) and CHOC at Mission. She is board certified in Pediatrics and Neonatal-Perinatal Medicine.

Dr. Sudeep Kukreja

Kukreja, Sudeep – MD

Sudeep Kukreja, M.D. is board certified in neonatal-perinatal medicine. Dr. Kukreja is the Associate Medical Director of the Neonatal Intensive Care Unit (NICU) and is the Medical Director of the Newborn Hearing Screening Program at CHOC and CHOC at Mission. Dr. Kukreja provides the full spectrum of neonatal critical care, with special interests in the management of high-risk infants, apnea and newborn hearing.

 

Dr. Kukreja served his fellowship and residency at UCI Medical Center in Orange and at Thomas Jefferson University Hospital in Philadelphia, respectively. He completed his internship and medical training at King George’s Medical College in Lucknow, India. Dr. Kukreja is fluent in Hindi, Punjabi and Urdu.

 

Announcements

 

Arpan Global Charities – 2013 Mission Suyay to Latacunga, Ecuador

 

Arpan Global Charities 4th Annual Fundraiser Event, Silent Auction & Wine Tasting, Saturday, November 12th, 2011

 

Arpan global Charities

Arpan Global Charities

Arpan Global Charities embarked on its latest medical mission in January of 2010 to Amritsar, India, the hometown of its founder Dr. Sudeep Kudreja, a Neonatologist at Children’s Hospital of Orange County (CHOC) and Assistant Professor of Pediatrics at the University of California Los Angeles (UCLA). This mission marked the charity’s eighth trip abroad since its inception in 2005.

 

Arpan Global Charities
For additional information on Arpan Global Charities, please visit:
Photo not available

Kamran, Shahid – MD

Shahid Kamran, M.D. board certified in pediatric and neonatal-perinatal medicine and provides the full range of neonatal critical care services. Dr. Kamran serves as the Director on the Neonatal Intensive Care Unit (55-bed capacity), Pomona Valley Hospital Medical Center, Pomona, California.

 

Dr. Kamran served his fellowship at North Shore University Hospital in Manhasset, New York. He completed his residency and internship at Our Lady of Mercy, Bronx in New York. He is a graduate of Illama Igbal Medical College in Pakistan. Dr. Kamran speaks fluent Urdu.

Photo not available

Hillyard, Robert L. – MD

Robert Hillyard, M.D. is board certified in Neonatal-Perinatal Medicine and serves as the Medical Director of the Hoag Neonatal Intensive Care Unit (22-bed capacity). Dr. Hillyard attended medical school at the University of California, San Francisco. He completed both his internship and residency at Harbor-UCLA Medical Center. He performed his Neonatal fellowship at Harbor-UCLA Medical Center. Dr. Hllyard is member of the American Academy of Pediatrics.

 

Dr. Hillyard’s philosophy of care is having the privilege to be trusted with the care of your child. His special interests include a wide range of critically ill newborns including those with extreme prematurely, congenital heart disease and severe pulmonary hypertension. He has produced both basic science and clinical research, and is actively teaching newborn critical care and in the CHOC residency and fellowship programs. Dr. Hillyard’s honors include the Munzer family Award for excellence in research and teaching.

 

Dr. Stephen Hanten

Hanten, Stephen J. – MD

Stephen Hanten, M.D. is the Medical Director of the CHOC at Mission Neonatal Intensive Care Unit (22-bed capacity) and specializes in the care of pre-term infants. Dr. Hanten is board certified in both pediatrics and neonatology. He served his fellowship at Miller Children’s Hospital in Long Beach. His residency and internship were completed at Children’s Hospital of Orange County and at the University of California, Irvine, respectively. He received his medical training at Universidad Autonoma de Guadalajara in Mexico and at the University of California, Irvine.

Dr. Vjay Dhar

Dhar, Vijay – MD

Vijay Dhar, M.D. specializes in neonatal critical care, with particular interests in cytokines, nitric oxide, extracorporeal membrane oxygenation (ECMO) and high-frequency oscillating ventilation (HFOV) performed at CHOC. Dr. Dhar serves as the Medical Director of the CHOC Neonatal Intensive Care Unit (54-bed capacity), the Chief of the CHOC Specialists Neonatology Division, the CHOC Specialists Inpatient Network Development Director and an Associate Clinical Professor at UC Irvine.

Dr. Dhar is board certified in both pediatrics and neonatal-perinatal medicine. He completed his fellowship training at the Hospital for Sick Children in Toronto, and UCI Medical Center in Orange. He received his medical training at the Postgraduate Institute of Medical Education and Research in Chandigarh, India, and served his residency and internship at All India Institute of Medical Sciences in Chandigarh, and Gauhati Medical College in Gauhati, respectively.

Dr. Dhar is the past President of the California Association of Neonatologists. He was voted as one of Orange County’s Top Doctors in 2009 & 2010.

Publications

Publications† link:
Dr. Vijay Dhar Publications

( † Disclaimer: This search is powered by Google Scholar. Google Scholar is a third-party website with no affiliation with CHOC.)

Announcements

Dr. Dhar leads exceptional team effort saving newborn

Dr. Dhar discusses “Cool-Cap” technology for moderate or severe hypoxic-ischemic encephalopathy (HIE)

Dr. Dhar featured in Physician Connection Newsletter

Dr. Christine Bixby

Bixby, Christine E. – MD

Christine Bixby, M.D. is board certified in pediatrics and neonatology. Dr. Bixby is a CHOC Specialists Neonatologist who cares for patients in the NICU and she is a Clinical Instructor at UC Irvine.

 

Dr. Bixby completed her fellowship in neonatology at Harbor UCLA Medical Center, Torrance, California. Dr. Bixby also completed her residency and internship in pediatrics at Harbor UCLA Medical Center. She attended medical school at the University of California, Davis, School of Medicine, Davis, California. Dr. Bixby speaks conversational Spanish.

Dr. Daryoush Bassiri

Bassiri, Daryoush – MD

Daryoush Bassiri, M.D. is board certified in pediatrics and neonatology. Dr. Bassiri is a CHOC Specialists Neonatologist who cares for patients in the NICU and he is a Clinical Instructor at UC Irvine.

 

Co-Director of the CHOC Transport Program, Dr. Bassiri’s expertise comprises a wide array of neonatology. Dr. Bassiri completed his fellowship training in neonatology at Harbor-UCLA Medical Center. His residency training was completed at St. Luke’s-Roosevelt Hospital Center in Manhattan, New York. Dr. Bassiri also served as Chief Resident at St. Luke’s. He received his medical degree from St. George’s University School of Medicine in Grenada, West Indies. He completed his internship and residency at St. Lukes Roosevelt Hospital Center. His philosophy of care is to do no harm. Dr. Bassiri is fluent in Farsi and Kurdish.

Dr. Irfam Ahmad

Ahmad, Irfan – MD

Irfan Ahmad, M.D. is board certified in pediatrics and neonatology. Dr. Ahmad is a CHOC Specialists Neonatologist who cares for patients in the NICU and he is an Assistant Clinical Professor at UC Irvine.

 

Dr. Ahmad served as Chief Fellow and completed his Neonatal-Perinatal fellowship at the University of California Irvine (UCI) Medical Center. Dr. Ahmad completed his pediatric internship and residency at the University of Oklahoma, Oklahoma City. He attended medical school and completed a transitional internship at Aga Khan University in Karachi, Pakistan. Dr. Ahman served on the UCI faculty as an assistant professor of Pediatrics and continues to be involved in research at UCI. He is a co-investigator in a NIH sponsored study which involves measuring the effects of assisted exercise on body composition in preterm infants.

 

Dr. Ahmad’s philosophy of care is to provide the very best of care based on current research proven strategies. His special interests include infant growth and measurement of body composition. He is also interested in new strategies for prevention and treatment of necrotizing enterocolitis and spontaneous intestinal perforation in premature infants. Dr. Ahmad is fluent in Urdu and Hindi.

Neonatology

CHOC Children’s Specialists Neonatology Physicians are available around-the-clock to provide the most sophisticated, lifesaving care for critically ill newborns and to attend high-risk deliveries at select Orange County facilities for high-risk deliveries. These board certified pediatric subspecialists are CCS-accredited providers for the region and serve as medical directors for the two primary neonatal centers in Orange County: the 54-bed Neonatal Intensive Care Unit (NICU) at CHOC, and the 16-bed NICU located within CHOC at Mission. For infant birth weight under 2¼ lbs (< 1,000 grams), our Small Baby Unit is staffed with specially trained nurses, respiratory therapists and other supporting staff. CHOC is a member of the Neonatal Centers of Excellence Network. The CHOC Children’s Specialists Neonatology Division also directs neonatal programs at selected hospitals within the community.

More Than 35 Years of Experience in Neonatal Medicine

CHOC Children’s Specialists Neonatology Physicians are experts in treating the full spectrum of newborn illnesses and conditions. Working in a team centered care environment, the NICU programs at CHOC and CHOC at Mission have become recognized for providing the following specialized services:

  • More than 25 years experience in providing extra corporeal membrane
    oxygenation (ECMO), heart lung bypass, for critically ill infants
  • State-of-the-art respiratory therapy services
  • National recognition for the use of immunotherapy and biotherapy to treat
    neonatal infections
  • Nitric oxide treatment
  • 24-hour transport team, the only one in the region equipped with a pediatric oscillator
  • Cutting-edge management, support and treatment of newborns with cardiac conditions

The CHOC Children’s Specialists Neonatalology Division directs medical services provided for premature infants through the Early Development Assessment Center (EDAC). Assessment and treatment of apnea and other high-risk conditions is provided through regularly scheduled outpatient clinics at CHOC. CHOC Children’s Specialists Neonatology Physicians coordinate all necessary follow-up outpatient care, including coordination with pediatricians and planning for at-home care. We provide family-centered care with family involvement in the care and decision-making a priority from admission to discharge.
CHOC Children’s Specialists Neonatology Physicians strive to provide evidence-based quality care in our NICUs by our ongoing effort in the quality improvement arena. The declining rate of infection, increased use of breast milk and increased infant weight at the time of discharge, combined with a decreased length of hospital stay are evidence our ongoing efforts to improve quality.

Prenatal Counseling and Genetic Assessment : Comprehensive prenatal consultation, genetic assessment and advance treatment planning is provided for high-risk mothers. Having assisted in the development of NICU bioethics guidelines, CHOC Children’s Specialists Neonatology Physicians are available to assist families in making well-informed ethical choices.

CHOC Children’s Specialists Neonatology Physicians are in-house 24-hours-a-day, 7-days-a-week at CHOC, CHOC at Mission and select hospitals in Orange, Riverside and Los Angeles Counties and are available to attend high-risk deliveries.

Access to the Latest Clinical Research

The CHOC Children’s Specialists Neonatology Division participates in multi-center studies to assess the potential efficacy of new treatments, giving patients access to the newest medications and the latest medical advancements. Recent studies have evaluated the use of G-CSF to treat neonatal sepsis, and the efficacy of nitric oxide to treat pulmonary vasodilitation and severe pulmonary hypertension.

Watch CBS News Videos Online. This video from CBS News explains the recent FDA approval of the new Cool Cap technology and how it’s use can help save the brain of a baby that suffered oxygen deprivation at birth. Dr. Emily Senay joins Hannah Storm to explain how it works. This technology is now available at CHOC Children’s and is used by the CHOC Children’s Specialists Neonatology Division when indicated.

Participation in multi-center research studies allows CHOC Children’s Specialists Neonatologists to provide the most leading-edge therapies for treating a vast array of neonatal conditions.

Dr. Raymond Wang

Wang, Raymond Y. – MD

Board certified in Pediatrics, Clinical Genetics, and Clinical Biochemical Genetics, Raymond Wang M.D. is a member of the CHOC Specialists in the Division of Metabolic Disorders at the CHOC in Orange, California, where he is the director of the Lysosomal Storage Disorder Program, overseeing a vibrant clinic and productive research projects.

The Multi-Disciplinary Mucopolysaccharidosis Clinic is the only such clinic in the nation where multiple subspecialties (Pediatric Cardiology and Pediatric Orthopedics) evaluate the patient in conjunction with the Lysosomal Specialist. Borne from these synergies have been two collaborative translational research projects to date: one, a preclinical trial of intra-articular enzyme replacement therapy for mucopolysacchardiosis type one; the other, a study that identified carotid intima-media thickness as a possible discriminant for cardiac involvement in mucopolysaccharidosis.

Dr. Wang also collaborated with other members of the American College of Medical Genetics Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases to create guidelines for confirmation and management of infants identified by future newborn screening programs for lysosomal storage disorders. He is actively working on other research projects related to Hunter syndrome, Pompe Disease, Fabry Disease, Gaucher disease, and other inborn errors of metabolism.

Dr. Wang attended medical school at the University of California-Los Angeles, then completed his residency in pediatrics and medical genetics at the University of California-Los Angeles / Cedars-Sinai Medical Center. He went on to complete a fellowship in Clinical Biochemical Genetics at Cedars-Sinai Medical Center, where he performed research on the symptomatology of female Fabry disease heterozygotes. He was also co-investigator in an phase I/II clinical trial sponsored by Amicus Therapeutics of an oral small molecule chaperone therapy for selected patients with Fabry disease.

Select Publications

Wang RY, Bodamer OA, Watson MS, Wilcox WR; on behalf of the ACMG Work Group on Diagnostic Confirmation of Lysosomal Storage Diseases. Lysosomal storage diseases: Diagnostic confirmation and management of presymptomatic individuals. Epub ahead of print, Genet Med. 2011 Apr 15.

Reinstein E, Wang RY, Zhan L, Rimoin DL, Wilcox WR. Ehlers–Danlos type VIII, periodontitis-type: Further delineation of the syndrome in a four-generation pedigree. Am J Med Genet Part A 2011; 155: 742–747.

Sass JO, Fischer K, Wang RY, Christensen E, Scholl-Bürgi S, Chang R, Kapelari K, Walter M. D-glyceric aciduria is caused by genetic deficiency of D-glycerate kinase (GLYCTK). Hum Mutat. 2010; 31: 1280-1285.

Puckett R, Lorey F, Rinaldo P, Lipson M, Matern D, Sowa M, Levine F, Chang R, Wang RY, Abdenur JE. Maple syrup urine disease: further evidence that variant forms cannot be detected by newborn screening. Mol Genet Metab. 2010; 100: 136-142.

Wang RY, Cambray-Forker EJ, Ohanian K, Karlin DS, Covault KK, Schwartz PH, Abdenur JE. Treatment reduces or stabilizes brain imaging abnormalities in patients with MPS I and II. Mol Genet Metab. 2009; 98: 406-411.

Wang RY, Abe JT, Cohen AH, Wilcox WR. Enzyme replacement therapy stabilizes obstructive pulmonary Fabry disease associated with respiratory globotriaosylceramide storage. Journal of Inherited Metabolic Disease, Epub, 10/21/2008

Wang RY, Lelis A, Mirocha J, Wilcox WR. Fabry disease female heterozygotes are not just “carriers,” but have a significant burden of disease and impaired quality of life. Genet Med, 2007; 9: 34-45.

Wang RY, Kangarloo H, Jordan SH. Cystic Renal Disease. Emery & Rimoin’s Principles and Practice of Medical Genetics, 5th ed. Rimoin DL, Connor JM, Pyetriz RE, Korf BR, eds. 2007.

Wang RY, Jones JR, Chen S, Rogers RC, Friez MJ, Schwartz CE, Graham JM Jr. A Previously Unreported Mutation in a Currarino Syndrome Kindred. Am J Medical Genet Part A 2006; 140: 1923-1930.

Wang RY, Visootsak J, Danielpour M, Graham JM Jr. Midline defects in FG syndrome: does tethered spinal cord contribute to the phenotype? J Pediatr 2005; 146: 537-541.

Wang RY, Martinez-Frias ML, Graham JM Jr. Infants of Diabetic Mothers are at Increased Risk for the Oculo-auriculo-vertebral Sequence: A Case-Based and Case-Control Approach. J Pediatr 2002; 141: 611-617.

Wang RY, Earl D, Ruder RO, Graham JM Jr. Syndromic Ear Anomalies and Renal Ultrasounds. Pediatrics 2001; 108: E32.

Dr. Richard Chang

Chang, Richard C. – MD

Richard Chang, M.D. is a member of the CHOC Specialists Division of Metabolic Disorders and is board certified in both pediatrics and medical biochemical genetics. Dr. Chang is the assistant division chief of Metabolic Disorders at CHOC. Dr. Chang is Assistant Clinical Professor with the University of California, Irvine School of Medicine. He is a member of the Society for the Study of Inborn Errors of Metabolism (SSIEM) and the Society for Inherited Metabolic disorders (SIMD).

 

Dr. Chang is the director of the PKU Clinic where children with different disorders in phenylalanine metabolism are treated by a multi-disciplinary team. He is the principal investigator for research projects related to the use of new treatments in Phenylketonuria.

 

Dr. Chang’s interests are in the presentation, diagnosis, and treatment of inborn errors of metabolism, especially those with primary neurological symptoms. He participates as one of the attendings in the Neuro-Metabolic clinic, where children are followed by Pediatric Neurology and Metabolic Disorders specialists.

 

Dr. Chang serves as a Physician Informaticist at CHOC Children’s Hospital where he serves as a consultant for electronic health record implementation to enhance health care delivery.

 

Dr. Chang completed his residency training at Children’s Hospital of Orange County and attended medical school at the University of Iowa School of Medicine. Dr. Chang speaks Mandarin Chinese and Taiwanese Chinese.

 

Select Publications

 

Sass JO, Fischer K, Wang RY, Christensen E, Scholl-Bürgi S, Chang R, Kapelari K, Walter M. D-glyceric aciduria is caused by genetic deficiency of D-glycerate kinase (GLYCTK). Hum Mutat. 2010; 31: 1280-1285.

 

Puckett R, Lorey F, Rinaldo P, Lipson M, Matern D, Sowa M, Levine F, Chang R, Wang RY, Abdenur JE. Maple syrup urine disease: further evidence that variant forms cannot be detected by newborn screening. Mol Genet Metab. 2010; 100: 136-142.

 

Brautbar A, Wang J, Abdenur JE, Chang RC, Thomas JA, Grebe T, Lim C, Graham BH, Wong LJ The mitochondrial G13513A mutation is associated with Leigh disease phenotypes independent of complex I deficiency in muscle. Molecular Genetics and Metabolism 2008. 94:485-490.

Dr. Jose Abdenur

Abdenur, Jose E. – MD

Jose Abdenur, M.D. is board certified in Clinical Biochemical Genetics. Dr. Abdenur is the Medical Director of Metabolic Services at CHOC and the PSF Chief of the Metabolic Disorders Division and an Associate Clinical Professor at UC Irvine. He has special interest in the diagnosis and management of children with fatty acid oxidation defects and organic acidemias.

Dr. Abdenur served his fellowship in pediatric endocrinology, metabolism and nutrition at North Shore University Hospital, Cornell University Medical College, and completed his fellowship training in Biochemical Genetics, at the Denver Children’s Hospital and The Biochemical Genetics Laboratory at the University of Colorado Health Sciences Center, and in Clinical Genetics at Mount Sinai School of Medicine in New York. Dr. Abdenur completed his pediatric residency training at Hospital General de Ninos Dr. Pedro de Elizalde in Buenos Aires and received his medical training at the Universidad de Buenos Aires, Argentina.

Dr. Jose Abdenur, CHOC Specialists Division Chief of Metabolic Disorders, holds the position of genetic biochemical specialties Training Director for the UCLA Intercampus Medical Genetics Training Program which includes Clinical Biochemical Genetics and Medical Biochemical Genetics. He is responsible for approving the training of the biochemical residents and fellows received at their respective campuses, and oversees the trainees’ applications to the Boards. In addition, he leads the renewal of the ACGME Medical Biochemical Genetics Accreditation Program.

Publications

Publications† link:
Dr. Jose Abdenur Publications

( † Disclaimer: This search is powered by Google Scholar. Google Scholar is a third-party website with no affiliation with CHOC.)

Links

OC Family Magazine: Grow Up Great – Dr. Jose Abdenur

Videos

[youtubegallery]
“The Call” CHOC Documentary|http://www.youtube.com/watch?v=41v3q-aeqgc
[/youtubegallery]

Metabolic Disorders

The CHOC Specialists Metabolic Disorders Division is committed to diagnosing and caring for children with inborn metabolic diseases. Our treatment protocols and research are built upon the latest findings in our field, through a collaborative approach combining our expertise with other leading experts throughout the nation.

Genetic diseases are becoming increasingly recognized, and early testing, diagnosis and appropriate treatment interventions are critical to prevent complications, permanent disability, mental retardation and even death in children with inborn metabolic disorders. We are hopeful that many more metabolic conditions will be diagnosed by the use of new technologies currently available in newborn screening.

Testing and treatment for metabolic disorders is non-invasive and largely provided in an outpatient setting by the experienced treatment team based at Children’s Hospital of Orange County (CHOC). Testing includes specific metabolites in blood and/or urine (amino acids, acylcarnitines, carnitine, organic acids, mucopolysaccharides, etc.) and/or the assessment of enzyme activities.

Most treatment involves specific diets and formulas that are devoid of the metabolites that cannot be broken down in patients with metabolic disorders. Through treatment, we are able to prevent the natural course of the disease.

Clinical presentation of children with inborn metabolic diseases could be variable and non-specific, including failure to thrive, malnutrition, cyclic vomiting/dehydration, developmental delay/mental retardation or regression.

Patients are referred to our Program with unexplained or persistent:

  • Metabolic acidosis or ketosis
  • Increased lactic acid
  • Hyperammonemia
  • Abnormal liver function tests
  • Hypoglycemia
  • Neutropenia/Thrombocytopenia
  • Cataracts or Corneal opacities
  • Cardiomyopathy
  • Hepatosplenomegaly
  • Intractable seizures
  • Failure to thrive
  • Developmental delay or loss of milestones

Patients are sent to us for consultation when common work-ups based upon any of the symptoms listed above do not lead to a clear diagnosis.

Commonly treated disorders

  • Urea Cycle Disorders
  • Organic Acidurias
  • Amino Acid Disorders
  • Vitamin and Cofactor Disorders
  • Carbohydrate Metabolism Disorders
  • Fatty Acid Oxidation Disorders
  • Mitochondrial Disorders
  • Neurotransmitter Disorders
  • Lysosomal Storage Diseases
  • Peroxisomal Disorders
  • Other Inborn Errors of Metabolism: Creatine disorders, Purines & Pyrimidines disorders, Congenital Disorders of Glycosylation (CDG)

Advanced Research

There is growing interest and focus in the area of metabolic and genetic disorders. Our bench and clinical research focuses on early detection of inborn metabolic diseases using tandem mass spectrometry, new dietary treatment approaches for fatty acid oxidation defects and identification of defects in purines and pyrimides.

In-House Diagnostic Laboratory

We are in the process of validating a state of the art diagnostic laboratory for inborn errors of metabolism. Primary tests that will soon be performed by the laboratory include:

  • Organic acids
  • Amino Acids
  • Acylcarnitines
  • Carnitine (total and free)
Dr. Jasjit Singh

Singh, Jasjit – MD

Pediatric infectious disease subspecialist Jasjit Singh, M.D. specializes in international health issues, including vaccines for children. Dr. Singh is board certified in both pediatrics and infectious diseases. She received her fellowship training at Johns Hopkins University Hospital in Baltimore. Both her residency and internship were completed at New York Hospital, Cornell Medical Center in New York City. She received her medical training at Duke University School of Medicine in Durham, North Carolina. Dr. Singh was also voted as one of Orange County’s Top Doctors in 2009 & 2010.

 

 

 

 

Video

 

Dr. Delma Nieves

Nieves, Delma – MD

Dr. Delma J. Nieves has joined the Infectious Diseases Division of the CHOC Specialists. She is board certified in pediatrics and pediatric infectious diseases. She completed medical school at the University of Washington, Seattle, WA.

 

Dr. Nieves completed her pediatric residency training at Children’s Hospital of Orange County. Her fellowship training in pediatric infectious diseases was completed at UCLA School of Medicine, Los Angeles, CA. Her area of research is in Molecular Pathogenesis of Leptospirosis.

 

Dr. Nieves is available to see patients at CHOC Children’s Hospital of Orange County and other select Orange County locations.

Dr. Negar Ashouri

Ashouri, Negar – MD

Negar Ashouri, M.D. is board certified in pediatrics and pediatric infectious diseases. She completed medical school at St. George’s University School of Medicine in Grenada, West Indies. Dr. Ashouri completed her residency training at Children’s Hospital of Orange County, followed by a year as Chief Resident. She completed her pediatric infectious diseases fellowship training at Children’s Hospital of Los Angeles. Dr. Ashouri has special interest in neonatal and blood stream infections.

Dr. Felice Adler-Shohet

Adler-Shohet, Felice C. – MD

Felice Adler-Shohet, M.D. is board certified in pediatrics and pediatric infectious diseases and she is an Assistant Clinical Professor at UC Irvine.

Dr. Alder received her medical degree from Vanderbilt University School of Medicine in Nashville, Tennessee. She completed her internship and residency training at the Vanderbilt University Children’s Hospital. Dr. Adler-Shohet completed her fellowship training in pediatric infectious diseases at Miller Children’s Hospital, Long Beach and University of California, Irvine College of Medicine. Dr. Adler has special interest in tuberculosis and neonatal infections.

Infectious Disease

Infection can spread rapidly in a small child and involvement of a pediatric infectious diseases specialist can make all the difference. CHOC Specialists Infectious Diseases physicians are available for telephone consultation and inpatient evaluation 24-hours-a-day, 7 days a week at CHOC, CHOC at Mission and select area hospitals.

CHOC Specialists Infectious Diseases physicians are highly experienced, board certified pediatric subspecialists who understand the changing nature of infectious disease, particularly the complexities of pharmacodynamics in relation to a child’s immune status, developmental stage and possible environmental risks. They provide the early diagnosis and intervention necessary to prevent the complication and further spread of serious, life-threatening illnesses, including viral infections and complex or resistant bacterial and fungal infections. CHOC Specialists Infectious Diseases physicians also serve as medical directors of infection prevention. Their expertise has had a measurable impact in decreasing the spread of nosocomial and community infections and reducing the emergence of resistant pathogens. Infections in hospitalized children can evolve quickly and become life-threatening.

The Board Certified Pediatric Infectious Disease physicians at CHOC use their expertise to treat a range of problems – from the child in the community with meningitis or osteomyelitis, to the oncology patient with a complex fungal infection, to the fragile premature infant with sepsis. Their knowledge regarding new therapeutic modalities, emerging drug resistance, pharmacokinetics, and host-microbial interactions are key to successful outcomes for these children.

Early Intervention For Life-Threatening Conditions : The CHOC Specialists Infectious Diseases physician team is available 24-hours-a-day to provide expert diagnosis and treatment for acute or life-threatening conditions, such as:

  • Infectious diseases, including those caused by multi-resistant bacteria
  • Congenital and perinatal infections, including HIV
  • Opportunistic infections in the immunocompromised patient
  • Immunocompromised host
  • Respiratory infections
  • Viral and fungal infections
  • Community outbreaks

Inpatient services are complemented by the multidisciplinary care provided by other pediatric subspecialists, nurses, pharmacists, therapists, clinical dietitians, child psychologists and social workers at CHOC.

Outpatient Management for Chronic Conditions

Many conditions may be safely managed through home IVs and oral regimens. For the benefit of patients and their families, every effort is made to transition care to the home environment as quickly – and as safely – as possible. In the outpatient setting, there are several clinics each week for follow-up of hospitalized patients, and evaluation of new patients, such as those with recurrent fevers, travel issues, or international adoptees. There are also special clinics for patients with primary or acquired immunedeficiency. The ID physicians are available to answer questions from community physicians regarding vaccines, and other issues commonly encountered in general pediatric practice.

The CHOC Specialists Infectious Diseases physician team provides comprehensive outpatient care for:

  • HIV – an accredited program serving the greater Orange County area
  • Recurrent/periodic fever or fever of unknown origin
  • Viral hepatitis
  • Tuberculosis and other chronic infections
  • Coccidiomycosis and other endemic fungal infections
  • Travel medicine for children
  • Infections in primary immune deficiencies

Active Participants in the Latest Clinical Research

CHOC Specialists Infectious Diseases physicians serve as principal investigators for several clinical research studies, providing patients with access to the newest treatment options available. Recent studies have focused on the development of vaccines, antiviral medications, and anti-fungal treatments for common and serious infections.
CHOC Specialists Infectious Diseases physicians are also active participants in several nationwide collaborations for the study of a variety of infections in children.

Dr. Sameer Pathare

Pathare, Sameer S. – MD

Sameer S. Pathare M.D. is board certified by the American Board of Pediatrics and is an Assistant Clinical Professor, Pediatrics at UC Irvine School of Medicine. Dr. Pathare attended medical school at the Medical College of Wisconsin. He completed his internship, residency training, and served as Chief Resident at CHOC Children’s Hospital. Dr. Pathare has a particular interest in infectious diseases and is the author of published chapters on upper airway infections and foreign body ingestions.

 

His philosophy of care is to provide a wide scope of pediatric care for the hospitalized children at CHOC Children’s Hospital. He cherishes the opportunity to teach the next generation of pediatric medical students and residents.

 

Dr. Pathare received the CHOC Teacher of the Year award in 2006 and 2007. Dr. Pathare was voted as one of Orange County’s Top Doctors in 2009 and 2010, and was named a Physician of Excellence in 2011. Dr. Pathare serves on the PSF Board of Directors.

 

McGuire, Troy L. – MD

Dr. McGuire specializes in providing all aspects of pediatric care for the Hospitalist Service at CHOC. He enjoys teaching residents and has a special clinical interest in treating children with asthma. He received the CHOC Teacher of the Year award in 2002. Dr. McGuire is fluent in Spanish and is board certified in pediatrics. Recent publications include chapters on nephrotic syndrome and acute renal failure in the Pediatric Hospital Medicine textbook. He completed his residency at Children’s Hospital of Orange County and received his medical training at the University of California, San Diego School of Medicine. Dr. McGuire is also the Director of Medical Informatics at CHOC. Dr. McGuire was also voted as one of Orange County’s Top Doctors in 2009.

Le-Bucklin, Khanh-Van T. – MD

Khanh-Van Le-Bucklin, M.D. is the Associate Dean for Graduate Medical Education at the UC Irvine, School of Medicine.

 

She attended medical school at the University of California, San Francisco and residency at Stanford University. She has over a decade of experience in caring for children in a hospital setting. Her academic interests include hospital medicine and medical education.

 

She has received multiple teaching awards, and her work in medical education has been presented at national conferences and published in academic journals.

 

Dr. Antonio Arrieta

Arrieta, Antonio C. – MD

Antonio Arrieta, M.D. is board certified in Pediatric Infectious Diseases. Dr. Arrieta is the PSF Chief of the Division of Infectious Diseases and a Clinical Professor at UC Irvine.

Dr. Arrieta specializes in the treatment of serious community acquired and nosocomial infections and has added expertise in HIV medicine. He completed his fellowship at UCI-Memorial/Miller Children’s Hospital in Long Beach. He did his residency at Southern Illinois University in Springfield.

Dr. Arrieta is a graduate of Universidad Peruana Cayetano Heredia in Lima, Peru and speaks fluent Spanish. He was voted as one of Orange County’s Top Doctors for 2009 & 2010.

Academic Appointments

Clinical Professor, Pediatrics, University of California, Irvine, College of Medicine

Director Pediatric Infectious Diseases, CHOC, Orange, CA, 2004 – present

Director of Infectious Diseases Clinical Research, CHOC, Orange, CA, 2004 – present

Medical Director, KIDS Clinic (Pediatric HIV Center), 1991 – present

Principal Investigator, PACTG protocols (Sub Site of UCLA Main PACTG Site)

Research Projects

A Multicentre, Double- Blind, Comparative, Randomised Study to Evaluate the Efficacy and Safety of Micafungin (FK463) versus Liposomal Amphotericin B (AmBisome ®) in the Treatment of Invasive Candidiasis and Candidaemia Protocol FG-463-21-08. July 2003-July 2006. Principal Investigator: Antonio Arrieta, MD. (Fujisawa Healthcare Inc.)

A Pivotal Phase 3 Study of MEDI-524 (Numax), an Enhanced Potency Humanized Respiratory Syncytial Virus (RSV) Monoclonal Antibody, for the Prophylaxis of Serious RSV Disease in High Risk Children. Protocol #: MI-CP110. August 2004-October 2006. Principal investigator: Gary Goodman, MD; Co-investigator: Antonio Arrieta, MD (MedImmune)

A prospective, open label, non –randomized, naturalistic, long term safety surveillance, observational study of ciprofloxacin (either as oral suspension, oral tablets, or sequential IV  oral therapy or purely IV therapy) in the treatment of pediatric patients with a variety of infectious diagnoses. Pediatric quinolone use in pediatrics (QUIP) STUDY. Protocol 100201. October 2000- 2009. Principal Investigator: Antonio Arrieta, MD. (Bayer)- closed to enrollment- follow up only

Investigator Initiated Safety and Efficacy of Liposomal Amphotericin B (LAM-B) for the Prevention of Invasive Candidiasis in Preterm Infants. November 2003- September 2008. Principal Investigator: Antonio Arrieta, MD (Fujisawa Healthcare Inc– closed to enrollment

IRB #050805 and IRB#070751 (Season 1 and Season 2)- A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Children with Hemodynamically Significant Congenital Heart Disease MI-CP-124. August 2005-October 2008. Principal Investigator: Gary Goodman, Co-investigator: Antonio Arrieta, MD (MedImmune)

A Prospective, Non-Interventional Study to Evaluate the Incidence of Hospitalizations and Medically-Attended Lower Respiratory Tract Infection (MALRI) in Premature Infants 32 to 35 Weeks Gestational Age Who Are Not Recommended to Receive Prophylaxis for RSV (MI-MA 140). October 2006- September 2007. Principal Investigator: Gary Goodman, MD; Co-investigator: Antonio Arrieta, MD (MedImmune)

Screening of Mannose-Binding Lectin (MBL) Status in Pediatric Hematology/Oncology Patients. Protocol EZN-2232-03-S. June 2007-July 2009. Principal Investigator: Antonio Arrieta, MD (Enzon Pharmaceuticals)

A Multi-Center Study of the Safety, Tolerability, Pharmacokinetics, and Dose Escalation of Intravenous Recombinant Human Mannose-Binding-Lectin (rhMBL) in MBL Deficient Pediatric Hematology/Oncology Patients with Fever and Neutropenia. Protocol EZN-2232-03. June 2007-July 2009. Principal Investigator: Antonio Arrieta, MD (Enzon Pharmaceuticals)

A Phase I, Open-Label Study of the Safety and Tolerability of Repeated-Dose Micafungin as Antifungal Prophylaxis in Children and Adolescents Undergoing Hematopoietic Stem Cell Transplant Protocol 9463-CL-2103. May 2007-July 2009. Principal Investigator: Antonio Arrieta, MD (Astellas Pharma US).

A Phase 2, Randomized, Double Blind, Placebo Controlled Study to Evaluate a
Single Intravenous Dose of Motavizumab (MEDI-524), a Humanized Enhanced Potency, Monoclonal Antibody to Respiratory Syncytial Virus (RSV) for the Treatment of Children Hospitalized with RSV illness. (MI-CP-141). July 2007- November 2008. Principal Investigator: Antonio Arrieta, MD (MedImmune)

A Phase 3, Randomized, Double-Blind, Multicenter Study to Compare the Efficacy and Safety of Micafungin versus Amphotericin B Deoxycholate for the Treatment of Neonatal Candidiasis (PROTOCOL 04-0-199/ISN 9463-CL-2303)- June 2006-closed to enrollment. Principal Investigator: Antonio Arrieta, MD (Astellas)

Expanded Access Protocol for VariZig. June 2006-present Principal Investigator: Jasjit Singh, MD; Sub investigator: Antonio Arrieta, MD (Astellas) (Cangene/FFF)

IRB Studies

IRB#060640- Phase II Safety and Immunogenicity Study of Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) L1 Virus Like Particle (VLP) Vaccine (GARDASIL ®) in HIV infected Children > 7 to < 12 years of age. Protocol PACTG 1047. June 2006-closed to enrollment, patients in follow up. Principal Investigator: Antonio Arrieta, MD (PACTG)

IRB # 0611107- A Pharmacokinetic/Pharmacodynamic and Safety Evaluation of Oseltamivir (Tamiflu ®) for the Treatment of Children less than 24 months of age with Confirmed Influenza infection (CASG 114, DMID 06-0059). November 2006-2011. Principal Investigator: Negar Ashouri, MD; Sub investigator: Antonio Arrieta, MD (CASG-DMID)

IRB# 070211 – A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin (FK463) in Infants and Toddlers (> 4 months to < 24 months of age) with Esophageal Candidiasis or Other Invasive Candidiasis. Protocol 9463-CL-2102. February 2007-2011. Principal Investigator: Antonio Arrieta, MD (Astellas Pharma US)

IRB#1010111 Emergency Use Protocol for CMX001 in a Bone Marrow Transplant Patient with AdV, BKV, and CMB disseminated Infections. October 2010-2011. Principal Investigator: Antonio Arrieta, MD (Chimerix)

IRB # 1012127 Emergency Use Protocol for CMX001 in a Bone Marrow Transplant Patient with AdV, and CMB disseminated Infections. December 2010-2011. Principal Investigator: Antonio Arrieta, MD (Chimerix)

CURRENT STUDIES – PEDIATRIC INFECTIOUS DISEASES CLINICAL RESEARCH (Ongoing Clinical Trials)

IRB# 070329- A Phase 1, Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin (FK463) in Children (2-5 Years and 6-11 Years) and Adolescents (12-16 Years) with Esophageal Candidiasis or Other Invasive Candidiasis. Protocol 9463-CL-2101- March 2007-present. Principal Investigator: Antonio Arrieta, MD (Astellas Pharma US)

IRB# 080101- Phase 1B Study of the Safety, Tolerance and Pharmacokinetics of Oral Posaconazole in Immunocompromised Children with Neutropenia. Protocol P03579. January 2008-present. Principal Investigator: Antonio Arrieta, MD. (Schering-Plough).

IRB#80892 – International Fungal Network. August 2008-present. (International Fungal Network Coordinating Center)

IRB # 0809106- A Prospective, Open Label Study to Assess the Pharmacokinetics, Safety & Efficacy of Anidulafungin When Used to Treat Children with Invasive Candidiasis, Including Candidemia (Protocol A8851008). September 2008-present. Principal Investigator: Antonio Arrieta, MD (Pfizer)

IRB # 0810113- An Evaluation of the Safety, Efficacy, and Pharmacokinetics of Daptomycin in Pediatric Subjects Aged Seven to Seventeen Years with Complicated Skin and Skin Structure Infections Caused by Gram-Positive Pathogens (DAP-PEDS-07-03). October 2008-present. Principal Investigator: Antonio Arrieta, MD (Cubist)

IRB#90542 – An Open-Label, Multicenter, Multiple-Dose Pharmacokinetic Safety and Efficacy Trial of Maraviroc in Combination with Optimized Background Therapy for the Treatment of Antiretroviral-Experienced CCR5-Tropic HIV-1 Infected children 2-

IRB#911113 An Evaluation of the Pharmacokinetic Profile and Safety of a Single Dose of Daptomycin in Pediatric Subjects Aged Three Months to Twenty-Four months Who are concurrently receiving standard antibiotic therapy for proven or Suspected Gram-positive infection. (Cubist Pharmaceuticals)

IRB #100211 An open label, prospective pharmacokinetic/pharmacodynamic and safety evaluation of intravenous oseltamivir (Tamiflu) in the treatment of infants less than one year of age with influenza infection. February 2010-present. (F. Hoffman-LaRoche LTD)

IRB # 100216 A Phase 1, Open-Label, Multi-Center, Two-Part, Single-Dose, Parallel Design, Safety, Tolerance, and Pharmacokinetic Study of Orally and Intravenously Administered TR-701 FA in 12 to 17 year Old Adolescent Patients. March 2010-present. (Trius Therapeutics)

IRB#100432 Safety and Efficacy of Micafungin for the Treatment and Prevention of Fungal Infections in Neonatal and Pediatric Patients at CHOC. April 2010-present. (Astellas)

IRB#100435 Safety, Tolerability and Pharmacokinetics of Single Dose Intravenous Moxifloxacin in Pediatric Patients. (Bayer Healthcare)

IRB#100664 A Randomized, Double Blind Multicenter Trial to Evaluate the Safety and Efficacy of Sequential (Intravenous, oral) Moxifloxacin Versus Comparator in Pediatric Subjects with Complicated Intra-Abdominal Infection. July 2010-present. (Bayer Healthcare)

IRB#100771T Serum and Stool Calprotectin and Serum Lypopolysaccharide Binding Protein as Markers of Serious Infection and Necrotizing Enterocolitis in Premature Infants. August 2010-present. (PSF Tithe Committee)

IRB #110113 Prospective Surveillance to evaluate the Impact of the introduction of PREVNAR 13 on Streptococcus Pneumoniae invasive infections in Orange County, California. February 2011-present. (Pfizer)

IRB #110335 A Randomized, Placebo-controlled, Multi-Site Phase 2 Study Evaluating the Safety and Efficacy of Preemptive Treatment with CMX001 for the Prevention of Adenovirus Disease Following Hematopoietic Stem Cell Transplantation. April 2011-present. (Chimerix Inc.)

IRB #110337 Safety and Pharmacokinetics of Metronidazole in Premature Infants. April 2011-present. (Duke Clinical Research Institute)

IRB #110663 Treatment and Management of empyema at CHOC from 2000-2011. July 2011. (CHOC)

IRB#111088 Phase 3 SDIV ibuprofen vs. acetaminophen for fever reduction in children 0-16 years. (Cumberland Pharmaceuticals)

Publications

1. Ashouri N, Checchia PA, Arrieta AC. Kawasaki Disease. Pediatric Hospital Medicine, Second Edition 2008. pp 397-402

2. Arrieta A, Acute Rheumatic Fever . Pediatric Hospital Medicine, Second Edition. 2008 pp 412-415

3. Armenian SH, Singh J, Arrieta AC. Risk Factors for mortality resulting from blood stream infections in a pediatric intensive care unit. Pediatr Infect Dis J. 2005 Apr; 24 (4): 309-14.

4. Singh J, Arrieta AC. Management of Meningococcemia: an updated review. Indian J Pediatr. 2004 Oct; 71 (10): 909-13.

5. Berk DR, Falkovitz-Halpern MS, Hill DW, Albin C, Arrieta A, Bork JM, Cohan D, Nilson B, Petru A, Ruiz J, Weintrub PS, Wenman W, Maldonado YA; California Pediatric HIV Study Group. Temporal trends in early clinical manifestations of perinatal HIV infection in a population based cohort. JAMA. 2005 May 11; 293-(18) 2221-31.

6. Seibel NL, Schwartz C, Arrieta A, Flynn P, Shad A, Albano E, Keirns J, Lau WM, Facklam DP, Buell DP, Walsh TJ. Safety, Tolerability and Pharmacokinetics of Micafungin (FK-463) in Febrile Neutropenic Patients. Antimicrobial Agents Chemother. 2005. Aug; 49 (8): 3317-24.

7. Arrieta A. Treatment of Invasive Fungal Infections in the Pediatric Patient with Echinocandin therapy. Submitted and accepted for publication- Infectious Diseases Express Report
8. Anaisse EJ, Segal BH, Graybill JR, Arndt C, Perfect JR, Kleinberg M, Pappas P, Benjamin D, Rubin R, Aberg JA, Adderson EE, Adler FC, Akan H, Akova M, Almyroudis NG, Alexander BD, Andes D, Arrieta A, et al. Clinical Research in the lay press: irresponsible journalism raises a huge dose of doubt. Clin Infect Dis. 2006 Oct 15;43 (8): 1031-9.

9. Hope WW, Seibel NK, Schwartz CL, Arrieta A, Flynn P, Shad A, Albano E, Keirns JJ. Buell DN, Gumbo T, Drusano GL, Walsh TJ. Population Pharmacokinetics of Micafungin in Pediatric Patients and the Implications for Antifungal Dosing. Antimicrob Agents Chemother. 2007 Jul;51:3714-9.

10. Yellin AE, Johnson J, Higareda I, Congeni BL, Arriet AC, Fernsler D, West J, Gesser R. Ertapenem or ticarcillin/clavulanate for the treatment of intra-abdominal infections or acute pelvic infections in pediatric patients. Am J Surg. 2007 Sep; 194 (3):367-74.

11. Ashouri N, Singh J, Arriet A. Micafungin in Pediatrics: when one size does not fit all. Expert Opin. on Drug Metab. & Toxicol. 2008 April; 4 (4): 463-469

12. Bendig E, Singh J, Butler TJ, and Arriet AC. The Impact of the Central Venous Catheter on the Diagnosis of Infective Endocarditis Using Duke Criteria in Children with Staphylococcus aureus bacteremia. Pediatr Infect Dis J 2008;27:636-639

13. Queiroz-Telles F, Berezin E, Leverger G, Freire A, van der Vyver A, Chotpitayasunondh T, Konja J, Diekmann-Berndt H, Koblinger S, Groll A, and Arriet A. for the Micafungin Invasive Candidiasis Study Group. Micafungin vs Liposomal Amphotericin B for Pediatric Patients with Invasive Candidiasis: A Randomized Double-Blind trial. Pediatr Infect Dis J. 2008 Sep;27(9):820-6

14. Suesaowalak M, Cheung MM, Tucker D, Chang AC, Arriet A. Chlamydophila pneumoniae Myopericarditis in a Child. Pediatr Cardiol. 2009 Apr;30(3):336-9.

15. Smith PB, Walsh TJ, Hope W, Arriet A, Takada A, Kovanda LL, Kearns GL, Kaufman D, Sawamoto T, Buell DN, Benjamin DK jr. Pharmacokinetics of an Elevated Dosage of Micafungin in Premature Neonates. Pediatr Infect Dis J. 2009 May;28(5):412-5.

16. Benjamin DK, Smith PB, Arriet A, Castro L, Sanchez PJ, Kaufman D, Arnold L, Kovanda L, Sawamoto T, Buell D, Hope W, Walsh TJ. Safety and Pharmacokinetics of Repeat-Dose Micafungin in Young Infants. Clinical Pharmacology & Therapeutics 2010;87 (1) 93-99.

17. Antonio C Arrieta MD, Kathy Shea BA, Vijay Dhar MD, John Cleary MD, Sudeep Kukreja MD, Mindy Morris RNP, Ofelia Vargas-Shiraishi MS, Negar Ashouri MD, Jasjit Singh MD. Once Weekly Liposomal Amphotericin B as Candida Prophylaxis In Very Low Birth Weight Premature Infants; A Prospective, Randomized, Open-Label, Placebo-Controlled Pilot Study. Clinical Therapeutics 2010:32 (2) 265-271

18. Chuang M, Singh J, Ashouri N, Katz M, Arriet A. Listeria Meningitis after Influximab Therapy for Ulcerative Colitis. Journal of Pediaric GI and Nutrition 2010 Mar;50(3): 337-9.

19. Hope WW. Smith PB, Arriet A, Buell DN, Roy M, et al. Population pharmacokinetics of micafungin in neonates and young infants. Antimicrob Agents Chemother.2010 Jun;54(6):2633-7

20. Walsh Tj, Drisctoll T, Milligan PA, Wood, Arriet A. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Immunocompromised Children. Antimicrob Agents Chemother. 2010 Oct;54(10):4116-23.

21. Arrieta A, Singh J, Ashouri N, Vargas-Shiraishi O. Streptococcus pneumonie bloodstream infection in hospitalized children after implementation of pneumococcal conjugate vaccine. J Pediatr Infect Dis 2011; 6(2)

22. Green J, Singh J, Cheung M, Adler F, Ashouri N, Arriet A. A cluster of pediatric endemic typhus cases in Orange County, California: Case reports and literature review. Pediatr Infect Dis J. 2011 Feb:30(2):163-5

23. Benjamin D, Arriet A, Smith, Brian, Cohen-Wolkowiez M, Castro L. et al. Population Pharmacokinetics of Meropenem in Plasma and Cerebrospinal Fluid of Infants with Suspected or Complicated Intra-abdominal Infections. Pediatric Infectious Disease Journal (in press). 2011 Oct

24. Arriet A, Maddison P, Groll, A. Safety of Micafungin in Pediatric Clinical Trials. Pediatr Infect Dis J. 2011 Jun;30(6):e97-e102.

25. Nieves D, Arriet A, Singh J, Adler F, Ashouri N, McGuire T. Clinical and Laboratory Features of Pertussis in Infants at the Onset of a California Epidemic. J. Pediatr 2011, September 16.

26. Driscoll T, Yu L, Haydar F, Krance R, Nemecek E, Blumer J, Arriet A, et al. Pharmacokinetics and safety of intravenous voriconazole to oral switch in immunocompromised children compared to adults. Antimicrob. Agents Chemother. 2011 0: AAC.00531-11

27. Freire A, Arriet A, Stevenson P, Undre N. Pharmacolinetics of Micafungin in Pediatric Patients with Invasive Candidiasis and Candidemia. Submitted to The Pediatric Infectious Disease Journal. August 2011.

Presentations

1. Nieves D, Singh J, Lang D, McGuire T, Dhar V, and Arrieta, A. Etiology and Outcome of Nosocomial Blood Stream Infections (N-SBI) in very low birth weight neonates (VLBW-N). Poster presentation. Pediatric Academic Society. May 14-17 2005. Washington DC

2. Bendig E, Singh J, Butler T and Arrieta A C Cardiac Complications in Pediatric Patients with Staphylococcus aureus(SA) Bacteremia(SAB): A Retrospective Review Utilizing the Duke’s Criteria(Dk-C). Poster Presentation. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases, May 3-5, 2006. Basel, Switzerland

3. Bendig E, Arrieta A C, Butler T and Singh J, Venous Access Devices (VAD) as a Risk for Infective Endocarditis (IE) in Pediatric Staphylococcus aureus Bacteremia (SAB). Poster Presentation. 24th Annual Meeting of the European Society for Paediatric Infectious Diseases, May 3-5, 2006. Basel, Switzerland

4. Bendig E, Singh J, Butler T and Arrieta A C Resurgence of Staphylococcus aureus (SA) Bacteremia (SAB) in Children: Exploring the Changes in Epidemiology, Management and Outcome. Poster Presentation. 106th General Meeting of the American Society for Microbiology, May 21-25, 2006 Orlando, Florida

5. Cerny LM, McGuire T, Singh J and Arrieta A C- Incidence of Serious Bacterial Infections (SBI) in Infants < 60 days old with Respiratory Syncytial Virus (RSV) infection. Usefulness of the “Rochester Criteria (RC). Poster presentation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA

6. Arrieta A C, Seibel N, Kovanda L, Keirns J, Facklam D, Buell D, and Walsh TJ. Safety, Efficacy and Pharmacokinetics (PK) of Micafungin (mica) in Pediatric (ped) Patients (pts). Poster presentation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA

7. Walsh TJ , Driscoll TA, Groll AH , Arrieta AC, Klein N, Bradley J, Jafri HS, Schlamm HT, Wood N , Milligan P, Lutsar I. Pediatric Voriconazole Study Group. Pharmacokinetics, Safety, and Tolerability of Voriconazole in Hospitalized Children. Poster presentation. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA

8. Late breaker Abstract Safety and Efficacy of Micafungin vs AmBisome in Candida Infections in Pediatric Patients. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2006. San Francisco, CA

9. Arrieta A, Queiroz-Telles F, Berezin E, Leverger G, Freire A, Diekmann-Berndt H, Koblinger for the Micafungin Invasive Candidiasis Study Group. Micafungin versus liposomal amphotericin B (AmBisome®) in paediatric patients with invasive candidiasis or candidaemia. ECCMID Mycamine Symposium , April 2007. Munich

10. Arrieta A, Maddison, P, Groll AH. Micafungin in Pediatric Patients: Assessment of Safety in Clinical Trials. Poster Presentation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007. Chicago IL.

11. Singh J, Bendig EA, Vargas-Shiraishi OM, Wronski, SA, Ashouri N, Arrieta, AC Microbiology (Micro) of Community Acquired (CA) Blood Stream Infection (BSI) After Introduction of Streptococcus pneumoniae (SP) Conjugated vaccine and its impact on the reliability of traditional diagnostic criteria. Poster Presentation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007. Chicago IL.

12. Walsh TJ, Driscoll TA, Groll AH, Arrieta AC, Klein N, Bradley J, Jafri HS, Laws J, Schlamm HT, Troke PF, Wood N, Milligan P, Lutsar I . Population Pharmacokinetic (POP-PK) Analysis of Voriconazole (VRC): Developing a Rationale for Dosage in Pediatric Patients. Poster Presentation. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2007. Chicago IL.

13. Arrieta AC, Shea K, Dhar V, Cleary J, Kukreja S, Ashouri N, Singh J: Safety of Liposomal Amphotericin as a Once Weekly Antifungal Prophylactic Regimen in Very Low Birth Weight Premature Infants. Poster Presentation at ECCMID, Barcelona, Spain, April 2008.

14. Arrieta AC, Shea K, Dhar V, Cleary J, Kukreja S, Morris M, Ashouri N, Singh J: Safety and Efficacy of Liposomal Amphotericin B (L-AmB) as a Prophylactic Regimen for the Prevention of Candida Colonization and Systemic Infection in Very Low Birth Weight (VLBW) Premature Infants. Poster presentation at PAS, Honolulu, HI, May 2008.

15. Arrieta A, Maddison P, Groll AH. Micafungin in Pediatric Patients: Assessment of Safety in Clinical trials. Poster presentation at PAS, Honolulu, HI, May 2008

16. Freire A, Arrieta A, Undre N. Pharmacokinetics of Micafungin in Pediatric Patients with Invasive Candidiasis and Candidemia. Poster presentation at PAS, Honolulu, HI, May 2008

17. D.K.. Benjamin Jr , P.B. Smith, A. Arrieta, L. Castro, P. Sanchez, D. Kaufman, L. Arnold, L. Kovanda, T. Sawamoto, D.N. Buell, W.W. Hope, T.J. Walsh. Safety and Pharmacokinetics (PK) of Repeat-Dose Micafungin (MICA) in Neonates. Poster Presentation at ICAAC May 2008

18. AC Arrieta, N. Seibel, L. Kovanda, J. Keirns, D. Facklam, D. Buell, TJ Walsh. Safety, Efficacy and Pharmacokinetics of Micafungin in Pediatric Patients. Poster presentation at the European Academy of Pediatrics congress in Nice, France, October 2008.

19. Benjamin DK, Smith PB, Arrieta A, Castro L, Sanchez PJ, Kaufman D, et al. Safety and Pharmacokinetics of Repeat-Dose Micafungin in Neonates and Young Infants. Poster presentation at the 2009 Pediatric Academic Society (PAS) meeting.

20. Arrieta A, Seibel N, Walsh TJ, Arnold L, Groll AH. Micafungin for the Treatment of Pediatric Invasive Fungal Infections. Poster presentation at the International Symposium on Intensive Care and Emergency Medicine (ISICEM), Brussels, Belgium, March 24-27, 2009.

21. Arrieta A, Seibel N, Walsh TJ, Arnold L, Groll AH. Micafungin: Overview of Efficacy in Children. Poster presentation at the 2009 European Society for Paediatric Infectious Diseases (ESPID) meeting.

22. Arrieta AC, Maddison P, Groll AH. Micafungin: Overview of Safety in Children. Poster presentation at the 2009 European Society for Paediatric Infectious Diseases (ESPID) meeting. Brussels, Belgium, June 09-13, 2009

23. Arrieta AC, Vargas-Shiraishi O, Ashouri N, Adler F, Singh J. Streptococcus Pneumoiae Blood Stream Infections (BSI) in Hospitalized Children after Broad Utilization of Heptavalente Pneumococcal Conjugate Vaccine (PCV-7). Poster presentation at the 2009 European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009.

24. Ashouri N, Singh J, Vargas-Shiraishi O, Arrieta A. Clinical and Microbiological Factors Affecting Outcome in Hospitalized Children with Candidemia. Poster presentation at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009

25. Ashouri N, Singh J, Vargas-Shiraishi O, Arrieta A. Identification of Factors Affecting Incidence and Outcome of Candidemia in a Neonatal Intensive Care Unit for Developing Prophylaxis Strategies. Poster presentation at the 27th Annual Meeting of the European Society for Paediatric Infectious Diseases (ESPID), Brussels, Belgium, June 09-13, 2009

26. R. Avery, F.M. Marty, L. Strasfeld, I. Lee, A. Arrieta, S. Chou, S. Villano. Oral Maribavir (MBV) for Treatment of Resistant or Refractory Cytomegalovirus (CMV) Infections in Transplant Recipients. Oral Presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC).San Francisco, California, September 12-15, 2009.

27. Ashouri N. Arrieta AC, Vargas-Shiraishi O, Adler F, Singh J. Staphylococcus aureus (S aureus) Bacteremia in Hospitalized Infants Less Than Three Months of Age. Poster presentation at the 49th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC). September 2009, San Francisco, CA

28. Arrieta, AC, Vargas-Sharaishi O, Singh J, Ashouri N, Kukreja S, Dhar V. Impact of intra-abdominal pathology in late onset blood stream infections in neonatal intensive care patients. Poster presentation to the 28th Annual Meeting of the European Society for Paediatric Infectious Diseases, Nice, France, May 4-8, 2010

29. Smith PB, Apparelli EV, Castro LM, Valencia G, Bidegain M, A Arrieta, Benjamin DK, et al. Pharmacokinetics and Safety of Meropenem in Young Infants with Intra-Abdominal Infections. Poster presentation at the 2010 Pediatric Academic Society (PAS) annual meeting, Vancouver, Canada. May 1-4.

30. Singh J, Ashouri N, Nieves, D, Mcguire T, Arrieta A. Clinical and Laboratory Features of Pertussis During a California Epidemic. Poster presentation at the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, September 12-15, 2010

31. Hoy Z, Singh J, Vargas-Sharaishi O, Arrieta A. Central line associated blood stream infections in pediatric patients with short bowel syndrome. Poster presentation to the American Society for Microbiology. New Orleans, May 2011.

32. Fisher J, Singh J, Ashouri N. Arrieta A.C., Adler F, Nieves D. Outcome of late onset neonatal sepsis due to bacteremic urinary tract infections. Accepted to present at the 7th World Congress of the World Society for Pediatric Infectious Diseases. Melbourne, Australia. November 2011

Publications

Publications† link:
Dr. Antonio Arrieta Publications

( † Disclaimer: This search is powered by Google Scholar. Google Scholar is a third-party website with no affiliation with CHOC.)

Dr. Jeffrey Armstrong

Armstrong, Jeffrey – MD

Jeffrey Armstrong M.D. is board certified in Pediatrics and is an Assistant Clinical Professor, Pediatrics at UC Irvine School of Medicine. As a general pediatrician in the CHOC Specialists Hospitalist Division, Dr. Armstrong specializes in providing a wide scope of pediatric care for hospitalized children. He has a particular interest in bronchiolitis, hemolytic-uremic syndrome (HUS) and Henoch-Schonlein purpura (HSP).

 

Dr. Armstrong attended medical school at the Medical University of South Carolina. He completed his pediatric residency training at UC Irvine including a year as Chief Resident. He enjoys teaching medical students and residents in pediatrics. He received the CHOC Children’s In-Patient Teacher of the Year Award in 2003.

 

Dr. Katherine Andreeff

Andreeff, Katherine M. – MD

Katherine Andreeff M.D. is board certified in Pediatrics and is a Clinical Instructor, Pediatrics at UC Irvine School of Medicine. Dr. Andreeff attended medical school at Wayne State University in Detroit, Michigan. She completed her pediatric training residency, which included a chief residency at CHOC Children’s Hospital. She relishes teaching residents and speaks fluent Spanish.

 

Dr. Andreeff is active in meningitis research and is the author of a published chapter on renal tubular acidosis. She is affiliated with the American Medical Association and American Academy of Pediatrics. Her practice philosophy is to provide comprehensive and compassionate care. Dr. Andreeff was voted as one of Orange County’s Top Doctors in 2010 and was named a Physician of Excellence in 2011.

 

Dr. Behnoosh Afghani

Afghani, Behnoosh – MD (UCI)

Behnoosh Afghani, M.D. is board certified by the American Academy of Pediatrics in both Pediatrics and Pediatric Infectious Diseases. She received her medical degree from the University of Southern California, followed by residency training in pediatrics at University of California Irvine.

 

Dr. Afghani completed fellowship training in pediatric infectious diseases at the University of California Irvine/Miller Children’s Hospital. Dr. Afghani is a Clinical Professor in Pediatrics at the UC Irvine School of Medicine and a member of the Hospitalist Division. She is the Founder and Director of the Center for Future Health Professionals at UC Irvine. Dr. Afghani was also voted as one of Orange County’s Top Doctors for 2009 & 2010.

Hospitalist

The CHOC Specialists Hospitalist program is a timely, cost-effective service available to primary care physicians whose busy outpatient practices limit the amount of time available to care for hospitalized patients.

For Admissions Call: (714) 509-8400
To reach the CHOC Orange On-Call Hospitalists call: (714) 997-3000

CHOC Specialists Hospitalist physicians are board certified pediatricians who specialize in hospital-based medicine. They are available 24-hours-a-day, 7 days a week to provide comprehensive inpatient care, consult with specialists, and coordinate hospital services – all while remaining in contact with the primary care physician at both the Orange and Mission campuses.

Upon discharge, patients are immediately referred back to the primary care physician for follow-up care and management.

Expert Care for Critically Ill or Injured Patients

The CHOC Specialists Hospitalist physician team is highly experienced in providing general inpatient-level pediatric care at CHOC and at CHOC at Mission.
Convenience, Coordination & Continuity

The CHOC Specialists Hospitalist service offers several advantages for referring physicians and patients alike. With 24-hour availability, CHOC Specialists Hospitalist physicians are immediately available to:

  • Attend to patients as often as necessary
  • Consult with or provide updates to referring physicians
  • Consult with parents and family members
  • Arrange consultation with specialists as necessary
  • Order hospital tests or procedures and are immediately available to review results
  • Facilitate transfer of a patient between an intensive care unit and a medical floor
  • Access patients throughout the day to identify the optimal time for discharge

The County of Orange (CHDP) program recertifies existing CHDP providers every 3 years. Part of the Certification requires the provider holds Hospital Privileges at a minimum of one hospital OR may designate a Hospitalist Program to cover patients they need to admit to a hospital. For more details, please visit: DHCS.CA.gov/services/CHDP

 

Dr. Amit Soni

Soni, Amit – MD

Amit Soni, M.D. is board certified in pediatrics and pediatric hematology/oncology. Dr. Soni completed medical school at Saint George’s University in Grenada, West Indies. His residency training was completed at the University of Medicine and Dentistry of New Jersey and fellowship training was completed at Children’s Hospital of Orange County.

 

After completing his fellowship, Dr. Soni worked as a hemostasis/thrombosis clinical research fellow at Children’s Hospital of Orange County and earned additional certification in a UCI graduate program in clinical trials and product development.

 

Dr. Soni has special interest in Hemophilia and other bleeding disorders. He was awarded the distinguished, international Bayer Hemophilia Clinical Training Award. Dr. Soni is also the coordinator of the Hematology/Oncology Fellowship Program.

 

Dr. Geetha Puthenveetil

Puthenveetil, Geetha – MD

Dr. Puthenveetil completed her fellowship training at Children’s Hospital Los Angeles, University of Southern California, Pediatric Hematology/Oncology. She received her medical degree from St. John’s Medical College in Karnataka, India. She completed pediatric residency training at St. John’s Medical College Hospital and at New York Medical College in Valhalla, New York.

 

Dr. Puthenveetil is Director of the Red Cell Program and Research. She leads the comprehensive care program for patients with hemoglobinopathy, such as sickle cell disease and thalassemia. She was voted as one of Orange County’s Top Doctors for 2009 and 2010, and speaks fluent Hindi and Malayalam.

 

Dr. Diane Nugent

Nugent, Diane J. – MD

Medical Director of CHOC Hematology and Blood and Donor Services and Chief of the CHOC Specialists Division of Hematology, Diane Nugent, M.D. is board certified in both pediatrics and pediatric hematology/oncology. She specializes in all aspects of hematology, bone marrow failure, anemias, immune disorders, bleeding and clotting disorders. Specialized procedures include bone marrow biopsy, aspiration and lumbar puncture.

Dr. Nugent completed her fellowship training at Children’s Hospital Medical Center in Seattle and Fred Hutchinson Cancer Research Center. Her residency and internship training were completed at Denver Affiliated Hospitals in Colorado. She received her medical degree at the University of California, Los Angeles, School of Medicine. Dr. Nugent speaks fluent Spanish.

Dr. Nugent is specifically interested in blood disorders or bone marrow failure, bleeding and clotting disorders, and white cell and immune deficiencies. Dr. Nugent was recognized as 2005 Physician of the Year in Orange County and serves as chair of review subcommittees at NHLB1/NIH and HRSA Region IX program projects in the area of hematology.

Publications

Publications† link:
Dr. Diane Nugent Publications

( † Disclaimer: This search is powered by Google Scholar. Google Scholar is a third-party website with no affiliation with CHOC.)

Announcements

Dr. Diane Nugent honored with 2011 CalOptima Circle of Care Award

CHOC Specialists Hosts Successful 8th Annual Sickle Cell Disease Symposium

Dr. Diane Nugent lays foundation for recent FDA approval of Factor XIII to treat potentially fatal bleeding disorder

Videos

[youtubegallery]
Interview with Dr. Diane Nugent, Medical Director of CHOC Hematology and Blood & Donor Services and CHOC Specialists Division Chief of Hematology|http://www.youtube.com/watch?v=fmu6pr0cjrU
Dr. Diane Nugent discusses the importance of research for our children|http://www.youtube.com/watch?v=3jW-uX6_UPk
In this segment from American Health Journal, Dr. Diane Nugent talks about pediatric hemophilia|http://www.youtube.com/watch?v=wePWEI06zgQ
[/youtubegallery]

Hsieh, Loan B. – MD

Loan B. Hsieh, M.D. specializes in all aspects of hematology with an emphasis in Factor 13 deficiency, and rare bleeding disorders. Dr. Hsieh completed her fellowship in pediatric hematology/oncology and her residency in pediatrics at Children’s Hospital of Orange County. Dr. Hsieh is Director of all Hematology Ambulatory/Outpatient Services.

 

Dr. Hsieh received her medical training at the Medical College of Virginia in Richmond. She is board certified in pediatrics and pediatric hematology/oncology and speaks fluent Vietnamese.

 

Hematology

Committed to serving the pediatric community, the CHOC Specialists Hematology physicians and treatment team provide comprehensive, multidisciplinary evaluation and treatment for hematologic diseases. Care is based on the whole-child/family approach and provided within an atmosphere of compassion and support.

The most highly advanced care is available for all forms of congenital or acquired blood and bone marrow disorders:

  • Anemia, including sickle cell anemia and thalassemia
  • White cell immune deficiencies
  • Coagulation abnormalities, including hypercoagulation, hemophilia, Von Willebrand’s Disease and related bleeding disorders
  • Bleeding and clotting disorders as a result of illness or surgery in otherwise healthy children
  • Prevention of bleeding and clotting problems, with particular experience in caring for patients on cardiopulmonary bypass
  • Hemostatis/Thrombosis Program, including free educational materials for healthcare providers and parents
  • Outpatient care for anemia caused by ingestion of lead
  • Outpatient care with access to short-term infusions

Family Support and At-Home Care

To help patients and parents become more autonomous in disease management, extensive education is provided. A home healthcare program is also available so that, whenever possible, children may be at home with their families.

Regionally Recognized for Clinical Excellence : CHOC Specialists Hematology physicians are board certified pediatric hematologists/oncologists. They provide medical direction for the inpatient and outpatient hematology services provided at CHOC and CHOC at Mission. They also direct the CHOC Hemostasis/Thrombosis Program and the Blood and Apheresis Center.

CHOC Specialists Hematology physicians are part of the multidisciplinary physician team serving the CHOC Neonatal Intensive Care Unit (NICU) and Pediatric Intensive Care Unit (PICU). Inpatient services are complemented by the multidisciplinary care provided by other pediatric subspecialists, nurses, pharmacists, therapists, clinical dietitians, child psychologists and social workers at CHOC.

Internationally Recognized for Immune, Autoimmune and Inflammation Research

CHOC Specialists Hematology physicians play an integral role in the CHOC Immunology and Inflammation Research Consortium, collaborating with colleagues at Stanford University, Scripps Research Institute and the University of California campuses at Davis, San Diego and San Francisco. They have examined the role of genetic background and immune function in several large-scale research studies, to help identify children predisposed to damage from an overactive inflammatory response, autoimmune disease or immune deficiency.

Their efforts have resulted in world recognition and awards from several prestigious organizations, including the National Institutes of Health, Centers for Disease Control, Maternal and Child Health and Development Bureau, Juvenile Diabetes Foundation and Arthritis Foundation.

CHOC Specialists Hematology physicians also participate in clinical research with pharmaceutical companies, providing patients with access to the latest medications and treatment available.

Dr. Bassam Younes

Younes, Bassam S. – MD

Bassam S. Younes M.D., is board certified in pediatrics and pediatric gastroenterology/nutrition and is a Clinical Professor at UC Irvine.

 

Dr. Younes treats the full spectrum of pediatric gastro-intestinal disorders and diseases. . He completed his fellowship training at UCLA Children’s Hospital in Los Angeles, California. Dr. Younes received his residency training at Semmelweis University School of Medicine, Maimonides Medical Center, Brooklyn, New York and attended medical school at Semmelweis University School of Medicine in Budpest, Hungary.

 

 

 

Announcements

 

Dr. Bassam Younes discusses GERD in the Neonate at NICU M&M Conference

 

Dr. Shaheen Idries

Idries, Shaheen I. – MD

Pediatric gastroenterologist Shaheen Idries, M.D. specializes in treating constipation, GER, inflammatory bowel disease and intestinal motility disorders. Dr. Idries is board certified in pediatrics and board admissible in pediatric gastroenterology and is an Assistant Clinical Professor at UC Irvine. She served her fellowship and internship at UCI Medical Center in Orange. Dr. Idries completed her residency at Winthrop University Hospital in Long Island. She is a graduate of Dow Medical College in Pakistan.

Dr. Kenneth Grant

Grant, Kenneth E. – MD

Kenneth Grant, M.D. specializes in the treatment and management of pediatric gastroenterology disorders, with particular emphasis in growth and development. Dr. Grant is board certified in pediatric gastroenterology. He served his fellowship at Massachusetts General Hospital in Boston and completed both his internship and residency at Children’s Hospital of Buffalo in New York. He is a graduate of Albany Medical College in New York. Dr. Grant is a member of the CHOC Specialists Board of Directors and is an Assistant Clinical Professor at UC Irvine. Dr. Grant was also voted as one of Orange County’s Top Doctors in 2010.

Gastroenterology

With multiple offices throughout the greater Orange County area, plus consultative services available at multiple hospitals, CHOC Specialists Gastroenterology physicians are available 24-hours-a-day, 7 days a week to help children experiencing chronic, painful or life-threatening symptoms. Our highly experienced pediatric gastroenterologists provide innovative, efficient treatment modalities to improve quality of life, and to reintegrate the child back to family and school activities as much, and as quickly, as possible.

The CHOC Specialists Gastroenterology Medical Director directs inpatient gastroenterology services at Children’s Hospital of Orange County, the only CCS-certified program serving the county. CHOC Specialists Gastroenterology physicians also provide medical directorship for the Pediatric GI Motility Program, a center for the investigation and treatment of motor disturbances, as well as functional problems involving the gastrointestinal tract.

24-Hour Consultation for Digestive, Nutritional and Liver Disorders

Through global expertise and individual professional areas of focus, the CHOC Specialists Gastroenterology team is able to provide treatment and services for a wide range of digestive, nutritional and liver problems, including:

We commonly treat:

  • Abdominal pain – acute and chronic
  • Diarrhea – acute and chronic
  • Inflammatory bowel disease
  • Celiac disease
  • Constipation
  • Weight loss – unexplained
  • Growth failure
  • Nutritional problems
  • Parenteral nutrition support – TPN and intravenous access devices
  • Enteral nutrition support – gastronomy, jejunostomy and enteral devices
  • Feeding problems and dysphagia
  • Gastroesophageal reflux
  • Esophagitis
  • Eosinophilic Esophagitis
  • Short bowel syndrome
  • Gastrointestinal motility disorders
  • Functional gastrointestinal disorders
  • Liver disorders and gall bladder disease
  • Gastrointestinal bleeding

Procedures offered include:

  • Upper and lower endoscopy
  • Dilation of strictures
  • Hemostasis maneuvers, including cautery, sclerosis and banding
  • Foreign body removal
  • Gastrostomy placement
  • pH monitoring studies, including traditional and Bravo
  • Impedance monitoring
  • Gastrointestinal manometry, including esophageal, antroduodenal, colonic, anorectal
  • Rectal suction biopsy
  • Liver biopsy

Inpatient services are complemented by the multidisciplinary care provided by other pediatric subspecialists, nurses, pharmacists, therapists, clinical dieticians and social workers at both CHOC and CHOC at Mission.

Family Support and At-Home Care

Treatment planning is based on the whole-child/family approach. CHOC Specialists Gastroenterology physicians examine children and talk to parents to fully evaluate both the physical and emotional needs of the child. Education is also provided, empowering patients and their families to actively participate in care.

Specialized training and comprehensive support for outpatient parenteral and enteral nutrition is provided to help children remain within the home environment.

Active Participants in the Latest Clinical Research

CHOC Specialists Gastroenterology physicians serve as principal investigators for several clinical research studies, providing patients with access to the newest treatment options available. Recent activities have included a variety of medication trials.

Gastroenterology & Nutrition

Mitchell Katz, M.D. Division Chief
Kenneth Grant, M.D. Assistant Division Chief & Gastroenterology Section Chair
Shaheen Idries, M.D.
Michael Wang, D.O.
Bassam Younes, M.D.
Jeffrey Ho, D.O.
Anup Patel, M.D.
Ashish Chogle, M.D.
Gregory Wong, M.D.
Kimberly Silva, M.D.
Keren Appel, M.D.
Katie Ho, RN, MSN, CPNP
Ellen Schonfeld, RN, MSN, CPNP Coordinator – CHOC Eosinophilic Esophagitis Clinic
Janice Fredrickson, RN CCS Case Manager
Susan Alcantara, Office Manager
Yesenia Romero-Hernandez, Procedure Scheduler

Multidisciplinary Feeding Team

Mitchell Katz, M.D. Director
Amber Zaragoza, Financial Coordinator
Natalie Adame, RN,MSN, CPNP Coordinator
Jasmine Busto, RN, MSN, CPNP Coordinator

Dr. Lien Trinh

Trinh, Lien N. – MD

Lien N. Trinh, M.D. is board certified in pediatrics and in pediatric endocrinology. Dr. Trinh completed her fellowship training in pediatric endocrinology at Mount Sinai School of Medicine in New York. She served her internship and residency at St. Vincent’s Catholic Medical Center, New York Medical College and received her medical degree at St. George’s University, School of Medicine in St. George, Grenada. Dr. Trinh is fluent in Vietnamese.

Dr. Nikta Forghani

Forghani, Nikta – MD

Dr. Nikta Forghani is board certified in pediatrics and pediatric endocrinology. She completed her fellowship training in pediatric endocrinology at the Lucile Packard Children’s Hospital at Stanford University and she served her internship and residency at Children’s Hospital and Research Center in Oakland, California where she was Chief Resident.

 

Dr. Forghani received her medical degree from the University of California at Davis. Her areas of research interest include estrogen replacement therapy in adolescents with ovarian failure and Hypothyroxinemia and Prematurity. Dr. Forghani is fluent in Farsi and Spanish.

 

Dr. Timothy Flannery

Flannery, Timothy K. – MD

Tim Flannery, M.D. is board certified in pediatrics and in pediatric endocrinology and diabetes and is a Clinical Instructor at UC Irvine.

 

Dr. Flannery has a special interest in diabetes and growth disorders in children. He completed his fellowship in pediatric endocrinology at Baylor College of Medicine in Houston, Texas. Dr. Flannery completed his residency training at Loma Linda University Medical Center. He attended medical school at Oral Roberts University School of Medicine in Oklahoma. Dr. Flannery was also voted as one of Orange County’s Top Doctors in 2010.

Dr. Mark Daniels

Daniels, Mark W. – MD

Mark Daniels, M.D. is board certified in pediatrics and in pediatric endocrinology.

 

Dr. Daniels has expertise in diagnosis and management of growth, puberty and bone mineral disorders and in the management of diabetes mellitus.

 

Dr. Daniels completed his residency and his fellowship training at the Lucile Salter Packard Children’s Hospital at Stanford. Dr. Daniels was voted as one of Orange County’s Top Doctors in 2009 & 2010.

 

Endocrinology

Regionally recognized for patient care excellence, the CHOC Specialists Endocrinology team provides comprehensive diagnosis and treatment of diabetes mellitus and endocrine disorders at both CHOC and CHOC at Mission.

The CHOC Specialists Endocrinology team offers several innovative specialty programs and outpatient clinics designed to enhance quality of life for patients. The team provides medical or administrative directorship for the Endocrinology and Diabetes programs at CHOC.

Our services are complemented by the multidisciplinary care provided by other pediatric subspecialists, nurses, pharmacists, therapists, clinical dietitians, child psychologists and social workers at CHOC, the only solely dedicated pediatric hospital serving Orange County.

Comprehensive Education, Treatment, Research and Support for Patients with Diabetes Mellitus

CHOC Specialists Endocrinology physicians direct the CHOC Diabetes Center, the first pediatric diabetes program in Southern California to be recognized for meeting and maintaining American Diabetes Association (ADA) standards of care guidelines.

Clinical programs offered through the Center include:

  • Outpatient treatment and education for new-onset and new-to-program diabetic patients
  • Comprehensive outpatient follow-up programs structured to ADA guidelines
  • Parent and patient support group services and educational programs provided by the PADRE Foundation
  • School, healthcare provider and community education
  • Insulin pump program
  • Treatment for children with Type I, non-insulin dependent diabetes mellitus

Specialty Programs for Endocrine Disorders:

  • Growth Disorders – including evaluation and treatment for children with Turner’s Syndrome and chronic renal failure, and hypopituitarism.
  • Weight Management – including specialized services for children and adults with Prader-Willie Syndrome.
  • General Endocrinology Clinic – for pituitary, thyroid, adrenal, gonadal and other hormonal disorders. Immediate evaluation and treatment is available for children with such urgent conditions as newly diagnosed congenital hypothyroidism and uncontrolled Graves’ Disease.

Access to the Latest Clinical Research

CHOC Specialists Endocrinology physicians participate in several areas of clinical research, providing patients with access to the newest medications and treatment. Through their efforts, the CHOC Diabetes Center has become one of the largest screening sites for the NIH-sponsored Diabetes Prevention TrialNet. Additionally, their pediatric growth and hormone research and treatment program is one of the largest in the state.

Dr. Adam Schwarz

Schwarz, Adam J. – MD

Adam Schwarz, M.D. is board certified in both pediatrics and pediatric critical care medicine and specializes in pediatric critical care medicine and is an Assistant Clinical Professor at UC Irvine.

 

Dr. Schwarz completed a combined Pediatric Critical Care Fellowship at Harbor-UCLA, Children’s Hospital of Orange County & King Drew Medical Center. He received his medical training at Stanford University School of Medicine and completed both his internship and residency at Stanford University Hospital. Dr. Schwarz previously served as the Director of the Pediatric Intensive Care Unit, University of Kansas, and as a pediatric intensivist at Phoenix Children’s Hospital. In 2007, he published “Blueprints Pocket Pediatric ICU.” Dr. Schwarz is fluent in Spanish, French and Malay/Indonesian.

 

Dr. Schwarz has written a book on pediatric intensive care, Blueprints Pediatric ICU, as well as several national journal articles on pediatric critical care topics including pediatric septic shock and severe acute asthma. He also supervises the clinical research program within the division of pediatric critical care, overseeing many different national multi-center clinical research studies in pediatric critical care, including studies of Therapeutic Hypothermia after Pediatric Cardiac Arrest (THAPCA), implementation of a sedation protocol for children with respiratory failure on mechanical ventilator support (RESTORE), inflammatory and genetic biomarkers of septic shock, biomarkers of acute lung injury (BALI), pharmacokinetics of sedation medications (PISA), neuro-developmental consequences of critical pertussis, inflammatory responses to critical influenza infection (PICFlu), and a CDC sponsored study investigating the effectiveness of the influenza vaccine on preventing critical illness in pediatrics. Many of these studies are coordinated in association with a national organization of large academic PICUs across the U.S. and Canada called the Pediatric Acute Lung Injury and Sepsis Investigators (PALISI)

 

Dr. Paul Lubinsky

Lubinsky, Paul S. – MD

Associate Director of the PICU at CHOC, Paul Lubinsky, M.D. specializes in pediatric critical care with expertise in the treatment of respiratory failure, traumatic brain injury and cardiac intensive care. He is board certified in both pediatrics and pediatric critical care medicine. He is President of the CHOC Specialists and a Associate Clinical Professor at UC Irvine.

As Medical Director and Chairman of the Joint Governance Committee for the CHOC Specialists, Dr. Lubinsky brings a wealth of clinical and cultural background to his work at CHOC and CHOC at Mission. Dr. Lubinsky was born in Zambia and served his internship at Groote Schuur Hospital and the Red Cross Children’s Hospital in Capetown, South Africa. In 1986 he served as Chief Resident at UCI Medical Center in Orange followed by a Pediatric Critical Care Fellowship at CHOC under the mentoring of Dr. Nick Anas. Throughout his career Dr. Lubinsky has been a passionate advocate of injury prevention in children and he has lobbied vigorously for community awareness and prevention of drowning. He has worked tirelessly to expand the pediatric subspecialty base of physicians available to serve the needs of Orange County children, in the process regionalizing pediatric tertiary care at CHOC and training the next generation of pediatric Critical Care specialists.

Dr. Lubinsky opened the CHOC PICU at Mission Hospital and served on the Board of Mission Hospital and as the first CHOC at Missions Chief of Staff. Dr. Lubinsky has served in the leadership of the PSF as a Board Member since 1993 and been directly involved in the group’s growth from 30 founding physicians to now over 140 physicians. Most recently he has served a key role on the UCI Affiliation Team. Dr. Lubinsky’s clinical expertise in the treatment of respiratory failure, traumatic brain injury, and cardiac intensive care keep him in constant demand as the Associate Director of the PICU at CHOC.

Dr. Lubinsky’s philosophy of practice merges a passion for clinical excellence with a focus on family centered care. According to Dr. Lubinsky, “when a child is admitted to the hospital, it can be just as scary for the parents as it is for the child. That’s why we treat the entire family with the greatest compassion and understanding.” This philosophy is key to Dr. Lubinsky’s approach to medicine – treating the entire family and involving parents in their children’s care. Dr. Lubinsky specializes in pediatric critical care, with expertise in the treatment of respiratory failure, traumatic brain injury and cardiac intensive care. He is quick to point out the key differences between a children’s hospital and a general hospital for adults that includes pediatrics as a small part of their business. He explains, “The level of expertise and experience at a children’s hospital cannot be matched. We perform patient rounds with a multidisciplinary team of doctors and clinical specialists, including pharmacists, nutritionists and social workers. And, we are experts in just about everything related to kids, including unusual disorders. If it’s rare, we can treat it. That kind of expertise is what really makes a children’s hospital, like CHOC, special.” He adds, “I am proud of CHOC and the work we do. Children have been referred here from as far away as Hawaii, Seattle and Arizona. We work hard to make sure every child who comes to us gets the best in patient care. All three of my sons were treated at CHOC for a variety of issues, ranging from a brain tumor to orthopedic problems. Our patients receive the same care we would expect for our own children.” As a dad and as a pediatric specialist, Dr. Lubinsky would not have it any other way. Dr. Lubinsky was also voted as one of Orange County’s Top Doctors in 2010.

Publications

Publications† link:
Dr. Paul Lubinsky Publications

( † Disclaimer: This search is powered by Google Scholar. Google Scholar is a third-party website with no affiliation with CHOC.)

Video

[youtubegallery]
CHOC physicians, patients and their families talk about how CHOC provides expert pediatric care|http://www.youtube.com/watch?v=FYhgKwYHaHY&NR=1
[/youtubegallery]

Announcements

Dr. Paul Lubinsky receives the “Simply the Best” Award for “Partner in Excellence”

Dr. Jason Knight

Knight, Jason M. – MD

Jason Knight, MD is board certified in pediatrics and pediatric critical care. Dr. Knight is Co-Director of the CHOC Transport Program and is a Assistant Clinical Professor at UC Irvine.

 

Dr. Knight received his medical degree from Eastern Virginia Medical School in Norfolk, Virginia. Dr. Knight completed his residency training, including a year as Chief Resident, at Harbor-UCLA Medical Center. His fellowship training in critical care medicine was completed at Harbor-UCLA Medical Center and CHOC Children’s Hospital of Orange County, California.

 

Dr. Knight has special interest in congenital heart disease, ARDS, pediatric transport and telemedicine. Dr. Knight was also voted as one of Orange County’s Top Doctors in 2009 and 2010.

 

 

 

Announcements

 

Dr. Jason Knight, PSF Critical Care Physician and Director of the CHOC Emergency Transport Services Team, profiled by OC Family Magazine

 

Dr. Jason Knight makes OC Metro’s Hot 25 List of Business Professionals